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ABSTRACT

Molecular Sensing and Imaging of Human Disease Cells and Their Responses to
Biochemical Stimuli
by

Lifu Xiao, Doctor of Philosophy
Utah State University, 2015
Major Professor: Dr. Anhong Zhou
Department: Biological Engineering
The overall goal of this dissertation is to develop noninvasive imaging techniques
that allow us not only to detect diseased cells but also to study the molecular mechanisms
underlying these diseases.
Atomic force microscopy and Raman spectroscopy are applied to measure cellular
mechanical properties (e.g. Young’s Modulus, adhesion force) and biochemical
composition of living cancerous vs. healthy (A549 vs. SAEC) human lung epithelial cells.
These biomechanical and biochemical properties can be utilized to differentiate between
cancerous A549 and healthy SAEC human lung epithelial cells. Furthermore, different
cellular responses to anticancer drug doxorubicin (DOX) treatment are also observed.
Using AFM and Raman spectroscopy, we can quantitatively measure biophysical
properties of different cells, as complementary parameters to other properties (e.g. gene
and protein expression), helping identify the states of diseased cells.
Another major task of this dissertation is to develop noninvasive imaging
techniques to detect cancer biomarker epidermal growth factor receptor (EGFR) at single
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cell level using advanced instrumentation. We first synthesized a gold nanorod (AuNR)based nanoprobe for single-cell imaging of EGFR using surface-enhance Raman
spectroscopy (SERS). SERS is able to quantitatively measure the EGFR expression level
in different breast cancer cell lines and map the cellular distribution of EGFR in single cells.
Moreover, SERS, as a noninvasive imaging technique, is able to monitor the process of
nanoparticle uptake by single cell. Due to the diffraction limit of optical microscopy, SERS
is unable to provide nanoscale imaging resolution. We then applied an AFM-based
simultaneous Topography and RECognition (TREC) imaging technique to image EGFR
with nanoscale resolution. TREC is first validated on mica surface and then successfully
utilized to map the EGFR distribution in fixed and living breast cancer cells at single
molecule level. In addition, we have explored the potential of a gadolinium-gold (Gd-Au)
composite nanomaterial as a dual functional (MRI-SERS) imaging probe. Using this
previous reported MRI contrast agent, we successfully apply SERS function in the
detection of EGFR in three cancer cell lines.
The last part of the dissertation is to study fat-responsive G protein-coupled
receptor 120 (GPR120), and its interaction with linoleic acid (LA). We have synthesized a
dual functional composite nanoparticle for SERS-fluorescence bimodal imaging of
GRP120 in living HEK293 cells. By SERS-fluorescence imaging, we are able to locate
GPR120 distribution in single cells. Moreover, we have observed a dose-dependent
GPR120 response to LA treatments using SERS. This work demonstrates the potential to
use SERS-fluorescence bimodal imaging technique for real-time detection of the
interaction between fatty acids and their receptors (e.g. GPR120, CD36).
(201 pages)
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PUBLIC ABSTRACT

Molecular Sensing and Imaging of Human Disease Cells and Their Responses to
Biochemical Stimuli
Lifu Xiao
Advancement in microscopic and spectroscopic techniques could significantly
improve our ability in the study and diagnosis of diseases. Especially, being able to image
and detect human diseases at the cellular and molecular level allows people to diagnose
diseases at early stages and to study the molecular mechanisms behind various diseases.
Currently, histopathological techniques are most widely used for prognosis and diagnosis
of human diseases. However, conventional histopathology requires a complex process of
sample preparation, which limits the diagnostic efficiency of this technique. More
importantly, it requires fixation of tissue or cell sample, making it unsuitable for the study
of dynamic cellular activities in the progress of diseases. This dissertation mainly discusses
the progress in development of noninvasive imaging techniques that can be applied to study
human diseases at the cellular level.
One approach is to use atomic force microscopy (AFM) and Raman spectroscopy
to quantitatively measure the biomechanical and biochemical properties of cells, and then
use these properties to differentiate between different cell types, or cells at different states.
Here we have utilized our tandem AFM-Raman spectroscopy system to differentiate
between cancerous and healthy human lung epithelial cells, and monitor their different
responses to anticancer drug treatments. Generally, this technique (AFM-Raman) can serve
as a complementary approach to study various diseased cells, providing additional
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information to help doctors identify diseases at an early stage and investigate the progress
of diseases.
Another approach is specifically target and image disease marker molecules using
advanced microscopic and spectroscopic techniques. Epidermal growth factor receptor
(EGFR), as a cancer marker molecule, has been used as a model to develop noninvasive
imaging methods. A nanoparticle-based imagine probe has been synthesized for specific
imaging of EGFR at a single cell surface using surface-enhance Raman spectroscopy
(SERS). Due to the noninvasive feature of SERS, it can monitor the receptor-mediated
endocytosis of a nanoparticle in real time. Furthermore, an AFM-based simultaneous
Topography and RECognition (TREC) imaging technique has been developed to localize
EGFR subcellular distribution with nanoscale resolution. This TREC technique exhibits
potential to monitor the binding between EGFR and its ligands at single molecule level.
A multimodal imaging nanoprobe, which integrates different imaging modalities
into one single nanoparticle, can incorporate advantages and compensate for weaknesses
of respective imaging techniques. In this dissertation, we have functionalized a previously
reported nanoprobe for magnetic resonance imaging (MRI), trying to incorporate SERS
function into this probe to realize MRI-SERS bimodal imaging. We have tested the SERS
performance of the probe by using it to detect EGFR in three human cancer cell lines. This
nanoprobe demonstrates the potential for in vivo MRI-SERS bimodal imaging with
improved sensitivity from SERS. In addition, we have synthesized another composite
nanoprobe for SERS-fluorescence bimodal imaging of a fat-responsive G protein-coupled
receptor 120 (GPR120). Fluorescence is used as a fast indicator while SERS is for accurate
localization of GPR120. Using this probe, we can also quantitatively measure the changes

vii
of GPR120 activities in response to fatty acid binding, showing the potential to study the
molecular mechanism of fatty acid chemoreception.
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CHAPTER 1
INTRODUCTION
1.1 RATIONALE FOR PROPOSED RESEARCH
Health is one of the most important fields in human research. Every year, billions
of US dollars are funded to support health-related studies, where thousands of researchers
all over the world devote their lives, trying to fight human diseases and provide a better
and healthier world. The comprehensive understanding of a disease and effective
development of therapies requires an understanding of disease mechanisms at cellular and
molecular levels. A typical example is the study of human tumors. Scientists have shown
that the process of carcinogenesis proceeds through different stages such as initiation,
promotion and progression. They found the occurrence of each stage is driven by different
external or internal factors through different molecular mechanisms (reviewed in [1]). Thus,
in order to monitor the cellular progress of cancer, or investigate the molecular mechanisms
of other human diseases, there is always a need to develop new methods with improved
accuracy and sensitivity, which can be applied in the detection and identification of single
specific agents or multiple interactive factors that cause human diseases.
Currently, histopathology is most commonly used tool for study and diagnosis of a
number of human diseases including most cancers [2]. Histopathology refers to the
microscopic examination of tissues in order to study the manifestations of diseases.
Conventional histopathology requires a complicated sample preparation process. For
example, it requires (1) fixation of tissue to retain characteristic peculiarities of shape and
structure; (2) sectioning to make micron-scale thin cuts for microscopic imaging; (3)
histological staining to identify various components (e.g. disease markers) in cells and
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tissues. Although the developments in digital pathology could substantially enhance the
efficiency and accuracy of disease diagnosis by automated nuclei detection, segmentation,
and classification [3], there still remains challenges in applying histopathology for disease
studies. One major limitation is that histopathological imaging needs cells and tissues to
be fixed (“killed”), which makes it incapable of monitoring dynamic changes of cells and
tissues in the process of disease progress. Noninvasive imaging techniques need to be
developed in order to study cellular mechanism of human diseases.
This dissertation communicates progress on the development of noninvasive
imaging techniques to identify human diseased cells. Biomechanical and biochemical
properties measured by atomic force microscopy (AFM) and Raman spectroscopy,
respectively, are used to distinguish between different types of cells and different cellular
responses to external stimuli. This combined AFM-Raman method is explored as a
biophysical approach to increase the understanding of disease mechanisms. Another
approach explored in this research is to build biocompatible imaging nanoprobes for
detection and mapping of biomarker molecules in human cells using advanced microscopic
and spectroscopic imaging techniques.
1.2 BACKGROUND
Since a more detailed background introduction is included in each technical chapter
from chapter 2 to chapter 6, here only a brief background is presented to cover several
important concepts in the dissertation.

3
1.2.1 Cellular biomechanics and biochemical compositions measured by AFM and
Raman
In past decades, researchers have made considerable efforts to establish the links
between measures of cellular biomechanics and human disease states. The relationships
between cell structure, cell biomechanics and disease states can be summarized in a
structure-property-function-disease paradigm [4] (Figure 1.1). This paradigm shows that
changes in subcellular structures, especially in the cytoskeleton, will induce alterations in
biomechanical properties, sequentially alter cell functions, and result in various disease
states. It is reported that biomechanical properties can contribute to the regulation of tumor
cell functions such as tumor progression, cell proliferation, motility, migration, invasion
and metastasis [5, 6]. In vitro studies have shown that cellular biomechanics including cell
stiffness and adhesion of cancer cells are often lower than that of their normal counterparts.
This is thought to be mainly due to differently organized cytoskeletal structures [7]—this
difference in mechanical properties also has been considered a “biomechanical marker” to
early diagnosis of cancers [8, 9]. As a nondestructive nanoscale technique, AFM has been
widely applied in the biomechanical studies for mammalian cells, especially for cancer
cells [8-12].
Raman spectroscopy, based on the inelastic scattering of the incident laser on target
molecules, is a molecular vibrational spectroscopic technique that can detect molecular
structural information used to identify specific subcellular biochemical compositions in
living cells [13]. Raman spectra provide highly specific and reproducible vibrational
fingerprints of different cell types. In addition, this noninvasive technique can conduct
rapid real-time cell detection under physiological growth environments. Previous Raman
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studies have shown that cellular biochemical compositions and molecular structures (e.g.
DNA/RNA, proteins and lipids) also exhibit differences in cells with different disease
states [14-17]. Several studies applying Raman spectroscopy in cellular investigations have
been summarized in Table 1.1. Since the differences of the Raman spectra are usually nonsignificant for different cell types, principal component analysis (PCA) is often applied on
the spectra to classify them into different categories.
In past years, the Zhou lab from Utah State University has conducted a series of
studies incorporating AFM and Raman analyses, together with other techniques, to
investigate the biomechanics and biochemical changes of mammalian cells under various
conditions. By using AFM and Raman spectroscopy, Wu et al. [18] observed alterations in
cyto-architectures, mechanical properties, and biochemical components of human breast
carcinoma cells (MDA-MB-435), when transfected with BReast cancer Metastasis
Suppressor 1 (BRMS1) gene. This gene has been shown to induce many phenotypic
alterations in MDA-MB-435 cells [19]. Tang et al. applied Raman spectroscopy, AFM,
and multiplex ELISA to investigate the biophysical responses (including biomechanics and
bio-spectroscopic responses) of human lung epithelial cells to short term exposure of diesel
exhaust particles [20]. Li et al. used the biochemical and biophysical properties, measured
by Raman and AFM, as an indicator to monitor serum-induced differentiation of
trophoblast derived stem-like cells [21]. All these studies have demonstrated the potential
of AFM and Raman as nondestructive methodologies to investigate human disease cells
and their metabolism at subcellular level.
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1.2.2 Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine
kinase (RTK) family of signaling proteins. It was the first mammalian signaling protein to
be fully characterized [22].

The activation of EGFR is normally controlled by the

interaction with their ligands such as EGF and TGF-α, providing cells with substantial
differentiation and growth advantages [23]. However, it has been found that aberrant
expression or activation of EGFR appears to be an important factor in both the initiation
and the progression of human caner [24-26]. For example, in human breast carcinoma
(EGFR positive), expression of EGFR was reported to support the existence of tumor cells
with aggressive potentials [27]. The expression level of EGFR in metastatic breast tumors
was often higher than primary tumors, indicating that EGFR was involved in the process
of metastasis [19, 28]. Overexpression and abnormal function of EGFR and its ligands have
been found in many different types of human cancers [26]; this makes it a great prognostic
indicator for the development of malignancies. Furthermore, therapeutic strategies have
been developed, using small biomolecules (e.g. monoclonal antibody, kinase inhibitors) to
block the binding of EGFR and its ligands, consequently blocking receptor activation and
transduction of post-receptor signals [29, 30].
1.2.3 Surface-enhanced Raman spectroscopy (SERS)
Surface-enhanced Raman spectroscopy (SERS) is a powerful analytical tool in
biological applications which has attracted considerable attention recently. SERS offers
extremely high enhancement and turns the weak inelastic scattering effect of photons into
a structurally sensitive nanoscale probe [31]. As a result, one can realize ultrasensitive
levels of detection and non-invasive tagging of specific bioanalytes in living cells and
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animals [32]. A key component of the SERS technique is the SERS-active nanoprobe. It is
usually composed of metal nanoparticle (NP, e.g. AuNP or AgNP) encoded with sensitive
Raman reporter molecules followed by the coating of mono- or multi-layer protective
polymers (e.g. silica, polyelectrolyte and PEG) which improve stability and
biocompatibility [33-36]. Several studies have reported using SERS probes to target cancer
cells in vitro or in vivo [33, 36-41], including measurement of EGFR [33, 37, 41]. However,
very little SERS studies were focused on EGFR cellular distribution, EGFR-mediated
bioprocess, and how EGFR is regulated by metastasis suppressors.
1.2.4 AFM and simultaneous Topography and RECognition (TREC) imaging
In past decades, AFM has become a powerful technique for analyzing the surface
structures at nanometer scale and the forces acting on them with piconewton sensitivity
[42, 43]. In terms of studying biological samples, AFM presents significant advantages
over other microscopic methods since it allows single-molecule level studies of the
structure and interaction of complicated biomolecules and cells with nanometer spatial
resolution [44]. It also allows samples to be measured in liquid phase, enabling the study
of dynamic interactions between biomolecules under physiological cell growth
environments. Simultaneous Topography and RECognition (TREC) imaging, a new AFM
technique based on the high-resolution topographic imaging and single-molecule force
measurement [45, 46], has been developed for receptor imaging with high spatial and
temporal resolution. This methodology provides information that is complementary to that
obtained by fluorescence and electron microscopy [47]. For example, TREC imaging has
been successfully used to visualize for the first time, the localization and distribution of
Na+-K+ ATPases in the inner leaflet of cell membranes at the single-molecule level [48].
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Also, by employing TREC, the local organization of Fcγ receptors on a single macrophage
cell has been determined at single-molecule level [49]. In addition to cell receptor imaging,
the TREC imaging technique has also been extensively used to monitor specific
biomolecules while they are undergoing biological processes. Wang et al. [45, 50, 51]
applied TREC to study the action of human Swi-Snf nucleosome remodeling complex and
its interaction with mouse mammary tumor virus promoter during the process of
nucleosome remodeling, describing the crucial role of ATP activation in the process. In
addition, they were also able to recognize the glycosylation process of biomolecules by
using TREC imaging, and distinguish normal and aberrant antibodies based on their
glycosylation [52].
1.2.5 Multimodal cancer imaging
Noninvasive cancer imaging, used to describe tumor anatomical structure and to
investigate tumor metabolism, plays an important role in early cancer detection and
localization [53]. Currently, there are several imaging modalities widely applied in cancer
research, such as magnetic resonance imaging (MRI) [54-57], photoacoustic (PA) imaging
[58-60], surface-enhanced Raman scattering (SERS) [61-63] and optical fluorescent
imaging [64-67]. Although each individual modality has specific advantages in cancer
imaging, none are able to support comprehensive structural and functional studies of
tumors independently. Thus, there has been an interest in developing multimodal
approaches to combine the advantages of these individual imaging modalities and to
compensate for their weaknesses. Recently, several composite nanoparticles have been
successfully synthesized and used in multimodal imaging applications [68-73]. Theses
composite nanoparticles are usually constructed by combining together different nano-
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components, which are effective contrast agents for different imaging modalities. For
example, Jin et al. [68] had synthesized an iron oxide and gold-coupled core-shell
nanoparticle to integrate both MRI and PA imaging, which provides remarkable contrast
enhancement in bioimaging. Despite the quickly growing interest in designing
multifunctional imaging contrast agents, it remains challenging to combine multiple
components to incorporate different imaging modalities while preserving particle size.
1.3 DISSERTATION OUTLINE
In chapter 2, I included a study that uses AFM and Raman to study human lung
cancer cells in response to short time chemotherapy (Figure 1.2). Young’s modulus and
adhesion force of human lung adenocarcinoma epithelial cell line A549 and non-cancerous
human primary small airway epithelial cells (SAECs) were measured by using AFM. It
was found that normal SAECs are stiffer and more adhesive than cancerous A549 cells.
Upon treatment with anti-cancer drug doxorubicin (DOX) for a short time (4 hr), both
biomechanical properties of A549 cells were found to be increased while those of SAECs
were decreased, implying that DOX induced response mechanisms are different between
the two types of cells (cancerous vs. healthy cells). Using Raman spectroscopy, we
measured the changes in subcellular biochemical compositions of both cell types before
and after DOX exposure.
In chapter 3, I included a study that investigates expression, spatial distribution as
well as the endocytosis of EGFR in single breast cancer cells using SERS (Figure 1.3). By
incubating anti-EGFR antibody conjugated SERS nanoprobes with an EGFR-overexpressing cancer cell line, A431, EGFR localization was measured over time and found
to be located primarily at the cell surface. To further validate the constructed SERS probes,
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we applied this SERS probes to detect the EGFR expression on breast cancer cells (MDAMB-435, MDA-MB-231) and their counterpart cell lines in which EGFR expression was
down-regulated by breast cancer metastasis suppressor 1 (BRMS1). The results showed
that SERS method not only confirms immunoblotting data measuring EGFR levels, but
also adds new insights regarding EGFR localization and internalization in living cells
which is impossible in immunoblotting method.
In chapter 4, I included a study that applies TREC imaging method to mapping the
distribution of EGFR on single breast cancer cells at single-molecule level (Figure 1.4).
Single molecule recognition using monoclonal antibody (anti-EGFR) tethered scanning tip
was converted to high resolution Topography and Recognition images. The recognition
efficiency was tested in a spatial-temporal manner by introducing EGF as a competing
ligand, when conducting TREC imaging of EGFR using antibody-tethered AFM tips. We
measured the density and distribution of EGFR on breast cancer cell lines—MDA-MB435 and BRMS1-transfected 435 cells. We further discussed the advantages of TREC
imaging

over

conventional

detection

methods

such

as

western

blot

and

immunofluorescence.
In chapter 5, I included a study that describes a novel hybrid Gd-Au nanocomposite
(Gd2O3@MCM-41@Au), and its application on SERS detection of EGFR (Figure 1.5). We
synthesized and characterized the Gd-Au nanocomposite, and further performed a series of
functionalization processes to make it capable of SERS detection.

We conjugated

monoclonal antibody (mAb) to specifically target EGFR in three different human cancer
cell lines: human nasopharyngeal carcinoma cell (S18), human epidermoid carcinoma cell
(A431), and human lung adenocarcinoma cell (A549). These cell lines are measured by
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SERS to express EGFR at different levels. In addition, we used SERS to mapping the
cellular distribution of EGFR on single cancer cells as well as to monitor the metabolism
of the antibody-targeted nanoparticles in real time. Combining our SERS study and the
MRI study conducted by our collaborators in China [74], we demonstrate the potential of
this Gd-Au nanocomposite as a multifunctional (MRI-SERS) nano-probe not only for the
early detection and localization of cancer in vivo, but also for the investigation of cancer
metabolism and biochemistry at single cell level.
In chapter 6, I included a study that describes a SERS-fluorescence dual functional
nanocomposite (CaMoO4:Eu3+@AuNR), and its application on SERS-fluorescence
bimodal

imaging

of

GPR120

(Figure

1.6).

The

composite

nanoprobe

CaMoO4:Eu3+@AuNR was synthesized, characterized and functionalized for specific
targeting of G-protein-coupled receptor 120 (GPR120). As a model to demonstrate the
SERS-fluorescence bimodal imaging, we used a HEK293 cell line transfected with a cDNA
sequence encoding a doxycycline (Dox)-inducible mature peptide of GPR120. Both SERS
and fluorescence imaging showed elevated signals on GPR120 positive cells. In addition,
the interaction between GPR120 and linoleic acid (LA) was also investigated by SERS.
In chapter 7, I gave a brief summary of this dissertation research and discussed
directions for future research.
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Table 1.1 Raman spectroscopy in cellular investigation
Application

Exemplary Observations (bands, cm-1)

Reference

Cell cycle

G1 (511, 658, 845, 1322), S (1541, 1600), G2/M (1273)

[75]

Stem cell

hESCs had higher DNA and RNA contents than

[76]

differentiation

differentiated cells (785, 811, 1090, 1320)

Cell death

Degradation of proteins (1005, 1342), DNA breakdown

[77]

(788), formation of lipid vesicles (1303, 1660)
Wound healing

Collagen content change (1665/1445 ratio)

[78]

Cancer

Excessive presence of lipid droplets (1300, 2850) in

[79]

detection

colorectal cancer stem cells
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Figure 1.1 Schematic of chemo-biomechanical pathways influencing connections among
subcellular structure, cell biomechanics, motility and disease state (image adapted from ref
[2]).

Figure 1.2 Biophysical and biochemical responses of human lung epithelial cells to
doxorubicin anti-cancer drugs measured by AFM and Raman spectroscopy.
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Figure 1.3 Schematic illustration of EGFR detection on single human cancer cells by
SERS.

Figure 1.4 Schematic of interaction between EGFR and anti-EGFR measured by TREC
imaging.
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Figure 1.5 (a) STEM image of the Gd-Au nanoprobe. (b) Schematic of the SERS
detection of EGFR using Gd-Au nanoprobes.

Figure 1.6 Schematic illustration of SERS-fluorescence bimodal nanoprobes for GPR120
detection.
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CHAPTER 2
NONINVASIVE DETECTION OF BIOMECHANICAL AND BIOCHEMICAL
RESPONSES OF HUMAN LUNG CELLS TO SHORT TIME CHEMOTHERAPY
EXPOSURE USING AFM AND CONFOCAL RAMAN SPECTROSCOPY1
2.1 ABSTRACT
Cellular biomechanical properties including cell elasticity and cell adhesion are
regarded as criteria to differentiate cancer cells and normal cells. In this study, the
biomechanical properties including the Young’s modulus and adhesion force of human
lung adenocarcinoma epithelial cell line A549 and non-cancerous human primary small
airway epithelial cells (SAECs) were measured by using atomic force microscopy (AFM).
It was found that normal SAECs are stiffer and more adhesive than cancerous A549 cells.
Upon treatment with anti-cancer drug doxorubicin (DOX) for a short time (4 hr), both
biomechanical properties of A549 cells were found to be increased while those of SAECs
were decreased, implying that DOX induced response mechanisms are different between
the two types of cells (cancerous vs. primary cells). Using Raman spectroscopy, we
measured the changes in (sub)cellular biochemical compositions of both cell types before
and after DOX exposure. Our ultimate goal is to find out the potential relationship between
the changes in biomechanics and biochemical compositions of lung epithelial cells in
response to anti-cancer drugs.
2.2 INTRODUCTION
In past decades, considerable cancer research has been carried out using traditional
biological methods that are based upon molecular genetics and gene signaling, but the roles
1

L. Xiao, M. Tang, Q. Li, A. Zhou, Non-invasive detection of biomechanical and biochemical responses
of human lung cells to short time chemotherapy exposure using AFM and confocal Raman spectroscopy,
Anal. Methods 5 (2013) 874-879.
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of cell biomechanics have been ignored, regardless of the mechanical nature of the invasion
process of cancer cells [1]. Mechanical properties regulate tumor cell functions such as
tumor progression, cell proliferation, motility, migration, invasion and metastasis [2, 3].
Recently, cyto-mechanical properties have received increasing attention as a potential
biophysical marker for new cancer diagnostics and therapeutics [4, 5]. The quantitative
analysis of mechanical profiles at the single-cell level can provide additional information
that is usually not available in traditional cell biology approaches but may be crucial to
assess and understand tumor prognosis and response to chemotherapy. Normal human
mammary epithelial cells (MCF 10) are found to be less deformable than malignant human
breast cancer epithelial cells (MCF 7); moreover, phorbol ester TPA-treated MCF-7 cells,
which have an 18-fold increase in the invasiveness and metastatic efficiency, are even more
deformable than before treatment [6].
In vitro studies have shown that cellular biomechanics including cell stiffness and
adhesion of cancer cells are often lower than that of their normal counterparts—this has
been considered as a target to early diagnosis of cancers [7, 8]. In addition, interactions
between cancer cells and anti-cancer drugs have recently emerged as topics of particular
interest, because understanding the mechanisms of biomechanics as well as biochemistry
in cell function would facilitate the understanding of biology of cancers and further the
development of new anti-cancer drugs. In addition to biomechanics, anti-cancer agents also
cause subcellular biochemical changes such as the regulation of DNA, protein and lipids
[9]. Studies have shown that chemotherapy would increase the stiffness of cancer cells [10,
11]. However, little is known about whether anti-cancer drug chemotherapy would lead to
synergistic cellular biomechanical and biochemical responses, or in return, how these
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cellular responses would influence the chemotherapy efficiency. This knowledge is
particularly important to further determine the role of biomechanics in cancer development
and further elucidate the potential relationship between biomechanics properties and
cellular composition changes induced by anti-cancer drugs.
Atomic force microscopy (AFM) [12], working on the basis of the interaction
between a sharp cantilever tip and the sample surface, has become a powerful tool for in
situ imaging biological samples in (near) physiological conditions, and quantitation of
biomechanical properties of living cells [13-16]. Cross et al. found that metastatic cancer
cells are not only much softer, but also less adhesive than benign cells by measuring living
human cells derived from patients [8, 16]. Lam et al. observed an increase in cell stiffness
of leukemia cells, which may be due to dynamic changes in the actin cytoskeleton, when
exposed to anti-cancer drug dexamethasone or daunorubicin [10]. Raman spectroscopy,
based on the inelastic scattering of the incidence laser on target molecules, is a molecular
vibrational spectroscopic technique that can detect molecular structural information used
to identify specific (sub)cellular biochemical compositions in living cells [17]. Recently,
Raman spectroscopy has been successfully applied to detect biochemical composition
changes in cancer cells under anti-cancer drug treatments [18, 19].
Measurement of the biomechanical and biochemical responses of normal vs.
cancerous cells to known chemotherapeutic agents is needed to further understand their
cell-drug interaction mechanism. Doxorubicin (DOX) is a well-established anti-cancer
drug widely used in the chemotherapy of a wide range of cancers such as breast carcinoma,
hematological malignancies and lung cancer [20]. By intercalation into the nucleus [21],
DOX inhibits the process of DNA replication and macromolecular biosynthesis, and
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consequently lead to tumor cell apoptosis. In addition to leading to the apparent inhibition
to cellular elements, DOX also induces changes in cellular cytoskeleton (actin filaments)
[22, 23]. There are substantial studies on the interaction between DOX and tumor cells [2426]. However, to our knowledge, no work specifically focused on DOX-induced
biomechanical and biochemical changes in cancer cells has been reported. In this study,
we applied AFM and Raman spectroscopy to detect the responses of lung carcinoma cell
A549 and normal primary small airway epithelial cells (SAECs), to short time (4hr)
exposure at the single cell level. Short-time chemotherapy exposure (e.g., 4 hr) has been
reported to be sufficient for cells to show distinct responses and develop preliminary drug
resistance [27]. As a matter of fact, anti-cancer drug therapy would not only interact with
cancer cells but also may influence physiological function of normal (healthy) cells. It is
of particular interest to investigate how normal and cancer cells respond to anti-cancer drug
treatment.
2.3 MATERIALS AND METHODS
2.3.1 Preparation of A549 cells and SAECs
Human lung carcinoma A549 cells (ATCC, USA) were cultured in F-12k medium
containing 5% fetal bovine serum and 1% penicillin-streptomycin (both from Invitrogen)
at 37 °C with 5% CO2 in a humidified atmosphere. Cells (approximately 106 cells/ml) were
passaged at 80-90% confluence and used for experiments. Human small airway epithelial
cells (SAECs) were cultured in SAGM medium containing growth factors (BPE,
hydrocortisone,

hEGF,

epinephrine,

insulin,

triiodothyronine,

transferrin,

gentamicin/amphotericin-B, retinoic acid and BSA-FAF) at 37 °C with 5% CO2 in a
humidified atmosphere.
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For AFM experiments, the cells were seeded on poly-L-lysine coated glass bottom
Petri dishes (MatTek Corp. USA) at a density of 1x105 cells per 2 mL of media. To
minimize background in Raman spectroscopy, a density of 1x105 cells per 2 mL of media
was placed on a cleaned magnesium fluoride (MgF2) optical window (United Crystals Co.,
Port Washington, NY).
2.3.2 Anticancer drug Doxorubicin (DOX) treatment
DOX (Sigma-Aldrich, St. Louis, MO) was dissolved in water and stored at 4 °C as
a stock solution (8 µM) within one week prior to use. A549 cells and SAECs were
incubated for 24 hr after seeding and then treated by DOX for 4 hr at a final concentration
of 70 nM (IC50 of A549 [28]). Drugs were washed away after 4 hr and cells were kept for
24-hr incubation. Cells were then ready for measurement.
2.3.3 Atomic Force Microscopy (AFM) measurement
In order to conduct AFM measurements, cells were prepared in one of two ways.
(1) To obtain the topography and deflection images, cells were fixed with 4%
paraformaldehyde for 10 min, and then rinsed by 1×Ca2+/Mg2+-free phosphate buffered
saline (PBS) buffer. Finally, the cells were imaged in PBS buffer. (2) To measure
biomechanical properties such as cell elasticity and adhesion, in situ measurements were
applied. Cells were measured in culture media without any pretreatment. The whole
measurement was accomplished within 1 hr, so that the experiment condition could be
considered reflective of the physiological condition of living cells.
Contact mode AFM controlled by Picoview software (Picoplus, Agilent
Technologies, USA) was applied on A549 cells and SAECs at room temperature in either
PBS buffer (0.01 M, pH 7.4) or cell culture media. AFM deflection images of cells were
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chosen in the imaging experiment. In the force measurement, sharp silicon nitride AFM
probes (tip radius, 20nm) were employed (Bruker Corp., USA). The spring constant of
AFM tips were calibrated as 0.10~0.11 N/m and Deflection Sensitivities were 45~50 nm/V,
using Thermo K Calibration (Agilent Technologies, USA). The approaching/retracting
speed of the AFM tip during the force curve measurement was 6 µm/s.
For biomechanics measurement, force-distance curves were recorded by AFM
instrument to get cell elasticity (Young’s Modulus, E) and adhesion force (maximum pull
force between AFM tip and cell surface during the retracting process of the AFM probe)
of individual cells. For each cell line, 12 cells were measured with over 15 force-distance
curves per cell to avoid spurious results [8]. Young’s modulus and adhesion force were
calculated via the Scanning Probe Image Processor (SPIP) software (Image Metrology,
Denmark) by converting the force-distance curves to force-separation curves and fitting
the Sneddon variation of Hertz model [29-31], which describes conical tips indenting
elastic samples.
Statistical analysis of the biomechanical property data were conducted by one-way
ANOVA (Origin9, USA). Significance of means comparison was evaluated by Tukey’s
range test. Same statistical analysis were performed in all chapters of this dissertation.
2.3.4 Fluorescence imaging of A549 cells and SAECs
Cell samples were stained for cytoskeletal and nuclear architecture according to
manufacturer’s protocol (Invitrogen). For staining, (1) cells were fixed with a 3.7%
formaldehyde (Electron Microscopy Sciences) solution in PBS for 10 min at room
temperature (RT); (2) cells were treated with 0.1% Triton X-100 (Sigma) in PBS for 3 min
at RT; (3) incubated with 1% bovine serum albumin (BSA) in PBS for 30 min at RT; (4)
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incubated with 1 unit of phallotoxins (cytoskeleton dye) in PBS for 30 min at RT; (5)
incubated with 300 nM of DAPI dihydrochloride (nucleic acid dye) in PBS for 3 min at
RT. Cell samples were washed with PBS for two times between each step. Then stained
samples were stored in PBS at 4oC prior to AFM/FL observation.
Fluorescence images were collected by an Olympus IX71 inverted fluorescence
microscope equipped with an Olympus DP30BW CCD camera. Images were collected by
Olympus DP-BSW Controller and Manager Software. Phase contrast images were
acquired with a 40× Phase lens (Olympus), Our IX71 fluorescence microscope was coupled
to a PicoPlus atomic force microscope (called AFM/FL) via a specially designed stage
(Agilent Technologies).
2.3.5 Data acquisition for Raman Micro-spectroscopy
The Raman spectra of A549 cells and SAECs were measured by a Renishaw inVia
Raman spectrometer (controlled by WiRE 3.0 software) connected to a Leica microscope
(Leica DMLM), equipped with a 785 nm near-IR laser (laser spot 10 × 3 µm line) that was
focused through a 63 × NA = 0.90 water immersion objective. 520.5 ± 0.1 cm-1 was the
standard calibration peak for the spectrometer with silicon mode at a static spectrum.
Samples of SAECs and A549 cells were cultured on magnesium fluoride (MgF2) and then
imaged in Earle's Balanced Salt Solution (EBSS). Raman spectra between 600 and 1800
cm-1 wavenumber were then recorded for 1 accumulation at 20s laser exposure at static
mode. Three different positions (nucleus, cytoplasm and membrane) in a cell were
measured. Thirty-two spectra were used to calculate an average for each group.
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2.3.6 Raman data analysis
Cosmic rays in raw spectra were removed using Renishaw Wire 3.3 software.
Because Raman spectra are affected by the physical properties of the samples and
background noise, it is necessary to perform mathematical processes to reduce systematic
noise, and enhance resolution of chemical compositions from target cells. In this work,
Raman spectra were smoothed by moving average smoothing to filter high-frequency noise.
Each Raman spectrum consists of many variables, but only a fraction of the variables
contains useful information for cell classification. Principal component analysis (PCA) [32]
was performed on the data set with the goal of defining a new dimensional space in which
the major variance in the original data set can be captured and represented by only a few
principal component (PC) variables and allowing the most important variables responsible
for these differences to be identified. In this work, PCA methods based on moving average
smoothing were performed as an attempt to extract useful information from raw spectral
data, and firstly applied to examine the differences among the groups of untreated and
treated SAEC and A549 at three locations (nucleus, cytoplasm and cell membrane) of cells.
All algorithms were implemented in Matlab R2010b (Mathworks Inc., Natick, USA).
2.3.7 Cell viability test
The cell viability was analyzed using LIVE/DEAD Viability/Cytotoxicity Assay
Kit (Invitrogen) according to the manufacturer’s instruction. Briefly, (1) Cells were
cultured in poly-D-lysine coated glass-bottom dishes (MatTek Cop. USA) and MgF2
substrate which was put in Petri dishes for 24 hr; (2) cells were then washed with PBS
twice; (3) 2 ml of mixed solution of 2 µM Calcein AM and 4 µM ethidium homodimer-1
(EthD-1) (both from Invitrogen) was added directly to cells, and incubated cells for 30 min

34
at room temperature; (5) cells were imaged using fluorescence microscope with DP30BW
CCD camera (Olympus IX71) to analyze the relative proportion of live/dead cells. Here, a
10× objective was used to observe fluorescence. Calcein AM is well retained within live
cells producing green fluorescence; however, EthD-1 enters cells with damaged membrane
and binds to nucleic acids, thereby producing a red fluorescence in dead or membranedamaged cells. Therefore, the live/dead cells were differentiated visually.
2.4 RESULTS AND DISCUSSION
2.4.1 Biomechanical properties and morphologies of A549 cells and SAECs
In this study, cancerous A549 cells and normal (primary) SAECs are imaged with
AFM directly in the culture media under physiological condition. Apparent differences in
cell morphology and ultrastructure between the two cell types can be observed in AFM
deflection images—primary SAECs are generally larger and more affluent in filamentous
cell junctions than the cancerous A549 cells (Figure 2.1). Furthermore, two biomechanical
properties, cell elasticity (Young’s modulus, E) and cell adhesion force, are quantitated by
AFM force-distance measurements. The average Young’s modulus of A549 cells and
SAECs are measured to be 12.007±4.381 kPa (n=210) and 25.227±9.274 kPa (n=187),
respectively. The average adhesion force of A549 cells and SAECs are measured to be
0.506±0.152 nN (n=190) and 0.819±0.243 nN (n=187), respectively. Both Young’s
modulus and adhesion force for A549 cells (tumor cell) are significantly smaller (p<0.01,
Figure 2.2) than that for SAECs (non-tumor cell); which is consistent with reported studies
[16, 33]. This result means tumor cells were softer and less adhesive than non-tumor cells.
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2.4.2 Biomechanical responses to chemotherapy
In order to study the morphological and biomechanical responses of A549 cells and
SAECs to short time chemotherapy, cells are exposed to 70 nM (IC50 for A549 cells) [34]
DOX for 4 hr, followed by AFM force measurement to detect the alteration of cell elasticity
and cell adhesion. The results are shown in Figure 2.2. Young’s moduli for A549 cells and
SAECs with DOX treatment (4 hr) are measured to be 19.756±8.489 kPa (n=195) and
20.486±9.066 kPa (n=180), respectively. Adhesion forces for A549 cells and SAECs with
DOX treatment are measured to be 0.839±0.291 nN (n=179) and 0.769±0.248 nN (n=195),
respectively. Young’s modulus of A549 cells significantly (p<0.01) increases with DOX
treatment, whereas that of SAECs decreases, resulting in the reduction of difference in cell
elasticity between the two cell types (the difference is not statistically significant, Figure
2.2a). The change in cell elasticity induced by DOX exposure might be attributed to the
rearrangement of cytoskeleton, especially to the reorganization of intermediate filaments
and actin filaments, which have been identified as the main determinants of cell
viscoelasticity [35]. It should be noted that although, consistent with previous cancer
studies [10, 11], the elasticity of tumor cells increases after chemotherapy, that of benign
cells decreases possibly due to alterations in cytoskeleton with focal loss of contractile
elements, which has been seen in cardiomyocytes [22]. In addition, the alteration in cell
adhesion between the control and DOX treated cells follows the same trend as that of
Young’s modulus—adhesion force of A549 cells increases under DOX treatment, while
that of SAECs decreases. This observed opposite biomechanical responses to DOX
treatment between cancerous and primary cells imply that the regulation of (actin)
cytoskeleton or related signaling pathways may be different between these two cell types
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[36].

The response in cell adhesion could be related to the variation of adhesive

macromolecules (e.g. proteins, polysaccharides) on the cell surface, which can be probed
by AFM force spectroscopy [30]. In another word, DOX treatment reduced the
biomechanical differences between A549 cells and SAECs.
By applying the coupled AFM/Fluorescence microscope system, we are able to
simultaneously obtain AFM, fluorescence and optical phase contrast images of the same
cell (Figure 2.3). It is found that A549 cells are with less organized cytoskeleton structures
(e.g. filamentous actin) than SAECs; upon DOX treatment, both cell lines exhibit apparent
change in cytoskeleton, confirming the results of biomechanical tests. Moreover, phase
contrast images for DOX treated A549 and SAEC displayed dark spots within cells that
indicated the presence of intracellular vesicles, which is known to occur during the
apoptosis induced by DOX [37].
2.4.3 Cellular biochemical changes induced by chemotherapy
In addition to cell morphology and cellular biomechanics, cancerous A549 cells
and primary SAECs, when exposed to DOX, also present differences in biochemical
composition, which are detected by Raman spectroscopy. Since DOX interacts with cells
primarily at nucleus, we mainly focus on the spectra collected on nucleus area (data of
cytoplasm and membrane area are shown in Figure 2.4) of each cell type (via confocal
setting in Raman measurement). Averaged Raman spectra of A549 cell and SAECs control
and DOX treatment groups at nucleus are shown in Figure 2.5a. Major Raman bands for
cellular biopolymers (i.e. nucleic acids, proteins, lipids and carbohydrates) are listed in
Table 2.1. Comparing with SAEC control group, the Raman peaks of A549 control
exhibited a pronounced rise at 672 cm-1 (C-S stretching mode of cytosine), 720 cm-1 (DNA),
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786 cm-1 (DNA & phosphdiester bands DNA) and 813 cm-1 (phosphodiester bands RNA).
This result would be consistent with previous findings that DNA is more abundant in
cancer cells than normal cells due to the more active mitosis and cellular turnover [38].
Upon DOX treatments, spectroscopic differences between A549 cells and SAECs in DNArelated Raman peaks are reduced, because DOX selectively targets A549 cells and prevent
DNA replication, lowering DNA level in A549 cells. This observation that intensities of
DNA peaks decrease after anticancer drug exposure is also consistent with previous studies
[9, 39]. Besides the nucleic acids, distinctions in proteins (937, 1006, 1034 cm-1) and lipids
(1450 cm-1) are also observed in the Raman spectra; cancerous A549 cells are less affluent
in proteins and lipids than primary SAECs. Unlike DNA, DOX treatment leads to elevated
protein and lipid levels in both A549 cells and SAECs.
Principal component analysis (PCA) can further distinguish the spectral differences
for both cell types before and after DOX exposure. In Figure 2.5b, an evident separation of
clusters of SAEC and A549 can be observed in PCA score plot, where the 1st principal
component incorporated 47% of the variance and the 2nd component 26%. Moreover, it is
noticed that SAEC clusters (with and without DOX treatment) sit closely each other,
compared to obvious separation of the two clusters of A549 control and A549-DOX group.
This observation implies the less effective impact of short term (4 hr) exposure of DOX on
the changes of SAEC spectra than those on A549 cells. PCA plots for cytoplasm and
membrane areas are presented in Figure 2.4.
In order to quantitatively identify how DOX treatment influenced the variation in
cellular bio-components, we selected some specific Raman peaks (labeled in Figure 2.5a)
related to DNA, proteins, lipids and compared the changes in their spectral intensities. 720
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cm-1 band is assigned to guanine band of DNA, 1006 cm-1 band the symmetric ring
breathing phenylalanine band in protein, and 1450 cm-1 the CH2 deformation of lipids and
proteins [33]. Since Raman intensities have a linear dependence on the concentrations of
particular molecular bonds of cellular bio-components, the changes in their characteristic
peak intensities reflect the alterations of corresponding biochemical compositions of cells.
As shown in Figure 2.6, for A549 and SAEC cells upon DOX exposure, Raman intensity
for DNA (720 cm-1) presented a slight decrease (SAEC cells didn’t show obvious DNA
changes), whereas the peak intensities for protein (1006 cm-1) and lipid (1450 cm-1)
exhibited a considerable increase (6% ~12%). The decrease in DNA Raman signal and the
increase in protein Raman signal could be caused by the DOX-induced cell apoptosis,
which leads to the degradation of DNA [40] as well as the up-regulation of p53, Bax and
MDM2 proteins in cell nucleus [41]. The increase in lipid related Raman peak is related to
the presence of intracellular lipid vesicles at cell surface (e.g. phosphatidylserine, granule)
[9, 42], which also are confirmed by phase contrast imaging (Figure 2.3). Furthermore, as
Figure 2.6 shows, the larger percentages of Raman intensity changes for A549 cells
indicates that cancer cells are more sensitive to DOX treatment, comparing with normal
SAECs. Fluorescence cell viability analysis (Figure 2.7) shows more A549 cells are found
dead than SAEC cells after 4 hr DOX treatment, although most are still alive under
experimental condition.
2.5 CONCLUSIONS
In conclusion, we applied AFM and Raman micro-spectroscopy to monitor the
cellular biomechanical and biochemical responses of cancerous (A549) and primary
(SAECs) human lung epithelial cells to short chemotherapy exposure (4 hr). A549 cells
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and SAECs show opposite variation in cell stiffness and cell adhesion—A549 cells
increasing while SAECs decreasing—with the treatment of anticancer agent doxorubicin.
A reduction in DNA and a rise in protein and lipid concentrations, due to the process of
DOX-induced cell apoptosis, are observed from Raman spectral changes. Our study
indicates cellular biomechanics, as a biomarker for cancer therapy, provides new
prospective to investigate the potential linkage between alterations of biomechanics and
cell biochemistry induced by cell-drug interaction. As a result, these new findings would
benefit new anti-cancer drug development. In order to fully understand how the DOX
treatments affect the cellular biomechanical and biochemical responses of human lung cells,
more work has to be done in a dose-dependent and time-dependent manner.
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Table 2.1 Tentative Raman band assignments of Small Airway Epithelial Cells (SAEC)
and human lung adenocarcinoma epithelial cell (A549).
Raman shift (cm-1)
SAEC

A549

Band assignment

624

624

Phenylalanine

643

643

C-C twist Phenylalanine

662

662

666

666

G, T-tyrosine-G backbone in RNA

672

669

C-S stretching mode of cytosine

719

719

C-C-N+ symmetric stretching in phosphatidylcholine

720

720

DNA

762

762

Tryptophan

786

785

813

813

Phosphodiester bands RNA

832

832

𝑃𝑂2− stretch nucleic acids

854

853

Tyrosine

880

881

Tryptophan

900

901

mode

C-S stretching mode of cystine (collagen type I)

DNA & phosphdiester bands DNA

Monosaccharides (b-glucose), (C-O-C) skeletal

48
939

939

Skeletal modes (polysaccharides)

961

961

Phosphate of HA; Calcium-phosphate stretch band

1006

1006

Phenylalanine

1034

1034

Phenylalanine

1066

1066

𝑃𝑂2− stretching; chain stretching; C-O, C-C

1070-90

Symmetric 𝑃𝑂2− stretching of DNA (represents more DNA

stretching
1070-90
in cell)
Phosphodioxy group (PO−
2 in nucleic acids); Lipid

1095

1095

1129

1129

C-C skeletal stretch transconformation

1158

1158

Lipids and nucleic acids (C, G and A )

1179

1176

Cytosine, guanine

1213

1213

1254

1254

Tyrosine, phenylalanine
Lipid; A,T breathing mode (DNA/RNA); Amide III

(protein)
1304

1304

CH2 deformation (lipid), adenine, cytosine

1306

1306

C-N stretching aromatic amines

1317-9

1317-9

1343

1342

carbohydrates)

Guanine (B,Z-marker)
G (DNA/RNA); CH deformation (proteins and
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1400-30

1400-30

γ(C=O) O- (amino acids aspartic & glutamic

acid)
1451

1450

CH2 deformation (nucleic acid, proteins,

lipids)
1579

1581

Pyrimidine ring (nucleic acids)

1608

1608

Phenylalanine, Tryptophan

1660

1661

Amide I

1740

1740

Collagen III

Band assignment is based on [43-51].
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Figure 2.1 AFM images of living (a) A549 and (b) SAEC cells. Cells are imaged in culture
media under physiological condition. Scale bar: 10 µm. Histograms of (c) Young’s
modulus and (d) adhesion force distributions of A549 cells and SAECs.Data are expressed
as mean±SD.
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Figure 2.2 Comparison of (a) Young’s modulus and (b) adhesion force of A549 cells and
SAECs control groups and DOX (70nM, 4hr) treated groups.Values represent mean ± SD
(bar) of multiple cells. *p<0.05, **p<0.01.
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Figure 2.3 AFM deflection (row 1), phase contrast (row 2) and fluorescence (row 3)
corresponding images of SAEC and A549 control and DOX treatment (70nM, 4hr),
obtained simultaneously using coupled AFM/FL microscope.Cells were fixed with 4%
paraformaldehyde. In fluorescence images, F-actin was stained with phalloidin and nucleus
was stained with DAPI. Scale bar: 10 µm, column 1 and column 2; 16 µm, column 3 and
column 4.
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Figure 2.4 Average Raman spectra and PCA analysis of A549 cells and SAECs for
cytoplasm (a, b) and membrane (c, d) areas of control and DOX treatment (70nM, 4hr)
experiment.
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Figure 2. 5 (a) Average Raman spectra and (b) PCA analysis of A549 cells and SAECs for
nucleus area of control and DOX treatment (70nM, 4hr) groups (n=32).
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Figure 2.6 Raman intensity of the 720 cm-1, 1006 cm-1 and 1450cm-1 bands of A549 cells
and SAECs under control and DOX treatment condition. 720 cm-1: DNA. 1006 cm-1:
Phenylalanine (protein), 1450 cm-1: CH2 deformation of lipids. Scale bar represents
standard deviation. Percentage numbers on column show the changes of peak intensity
after DOX exposure. *p<0.05, **p<0.01.
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Figure 2.7 Representative fluorescence images of cell viability test. Images of A549 cells
and SAEC control (column 1, 2) and with DOX treatment (column 3, 4) were exhibited.
Cells were stained with Invitrogen LIVE/DEAD Viability/ Cytotoxicity Assay Kit. Green
fluorescence presented live cells, whereas red fluorescence showed dead or membranedamaged cells. All images were obtained with 10× lens. These fluorescence images
together revealed that A549 cells and SAECs which were used for AFM (row 1, 2) and
Raman (row 3, 4) experiments were mostly alive.
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CHAPTER 3
IMAGING OF EPIDERMAL GROWTH FACTOR RECEPTOR ON SINGLE
BREAST CANCER CELLS USING SURFACE-ENHANCED RAMAN
SPECTROSCOPY2
3.1 ABSTRACT
Epidermal growth factor receptor (EGFR) is widely used as a biomarker for
pathological grading and therapeutic targeting of human cancers. This study investigates
expression, spatial distribution as well as the endocytosis of EGFR in single breast cancer
cells using surface-enhanced Raman spectroscopy (SERS). By incubating anti-EGFR
antibody conjugated SERS nanoprobes with an EGFR-over-expressing cancer cell line,
A431, EGFR localization was measured over time and found to be located primarily at the
cell surface. To further validate the constructed SERS probes, we applied this SERS probes
to detect the EGFR expression on breast cancer cells (MDA-MB-435, MDA-MB-231) and
their counterpart cell lines in which EGFR expression was down-regulated by breast cancer
metastasis suppressor 1 (BRMS1). The results showed that SERS method not only
confirms immunoblotting data measuring EGFR levels, but also adds new insights
regarding EGFR localization and internalization in living cells which is impossible in
immunoblotting method. Thus, SERS provides a powerful new tool to measure biomarkers
in living cancer cells.
3.2 INTRODUCTION
Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is
overexpressed in a variety of human cancers, including all breast cancer subtypes [1].
Overexpression of EGFR in breast cancer is generally associated with poor prognosis and
2

L. Xiao, S. Harihar, D.R. Welch, A. Zhou, Imaging of epidermal growth factor receptor on single
breast cancer cells using surface-enhanced Raman spectroscopy, Anal. Chim. Acta 843 (2014) 73-82
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high recurrence rates [2]. Since EGFR status is related to cancer progression, there has
been extensive research to develop agents targeting EGFR and its corresponding signaling
pathways [3-5]. Therefore, improved methods to quantify and measure function of EGFR
in breast cancer cells could improve diagnosis and treatment of breast cancer.
Currently, the most commonly used methods to assess EGFR status in clinical
cancer specimens are immunohistochemistry and immunofluorescence staining [6-8].
Quantification can be done using immunoblotting. However, these methods either need
cell fixation (immunohistochemistry and immunoblotting), or face the problem of photobleaching (immunofluorescence), rendering them non-suitable for measuring dynamic
alterations of cell receptors and ligands.
Surface-enhanced Raman spectroscopy (SERS) is a powerful analytical tool in
biological applications which has attracted considerable attention recently. SERS offers
extremely high enhancement and turns the weak inelastic scattering effect of photons into
a structurally sensitive nanoscale probe [9]. In turn, one can realize ultrasensitive levels of
detection and non-invasive tagging of specific bioanalytes in living cells and animals [10].
A key to the SERS technique is the metal nanoparticle (NP, e.g. AuNP or AgNP) encoded
with sensitive Raman reporter molecules followed by the coating of mono- or multi-layer
protective polymers (e.g. silica, polyelectrolyte and PEG) which improve stability and
biocompatibility [11-14]. Several studies have reported using SERS probes to target cancer
cells in vitro or in vivo [11, 14-19], including measurement of EGFR [11, 15, 19]. However,
very little SERS studies were focused on EGFR cellular distribution, EGFR-mediated
bioprocess, and how EGFR is regulated by metastasis suppressors.
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Metastasis suppressors are a relatively recently described family of molecules that
suppress the development of cancer metastasis without blocking primary tumor growth
(reviewed in [20]). Of the approximately 30 metastasis suppressors (genes) identified to
date, BRMS1 has been well characterized for its ability to regulate molecules that alter
cellular response to micro-environmental signals which can be different between
orthotopic sites (i.e., the mammary gland for breast cancer) and ectopic sites (i.e., sites of
metastasis) [21], thought to explain why metastasis suppressors allow primary tumor
growth, but not metastatic colonization. BRMS1 regulates EGFR [21] and osteopontin [22]
expression, phosphoinositide [23], NFκB [24] and PKA [25] signaling, connexin
expression and gap junctional intercellular communication [20, 26], all of which play
significant roles in cancer progression. The mechanism by which BRMS1 does these
myriad things is thought to be as part of SIN3 histone deacetylase regulation of chromatin
structure [27].
Understanding how BRMS1 directly impacts cellular responses to signals from the
microenvironment is thought to be key to defining the critical mechanisms of action.
Unfortunately, the tools to measure ligand-receptor or antibody-antigen interactions are
suboptimal for this purpose. Therefore, we designed a SERS probe based on
polyelectrolyte-coated gold nanorods (AuNRs) to specifically recognize and detect EGFR
molecules (via antibody-antigen interaction) on the cell surface of breast cancer cells.
Using an EGFR over-expressing cell line (e.g., A341), we validated the ability of the
antibody-conjugated SERS probe to measure EGFR distribution and internalization on
single cancer cells. Then, using BRMS1-expressing cells and comparing them to their
parental breast cancer counterparts, we demonstrated that our constructed SERS probe is
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able to distinguish EGFR levels in different cancer cells and provide spatial information of
EGFR expressed on single cancer cell surface.
3.3 MATERIALS AND METHODS
3.3.1 Materials
Ultrapure water (18 MΩ cm-1) was used in this work. All chemicals were purchased
from commercial source and were used as received: gold nanorods (5.1  1011 particles
mL-1, Nanopartz Inc., USA), monoclonal anti-EGFR antibody (Invitrogen). A431 cell line
was obtained from American Type Culture Collection (ATCC). MDA-MB-435 (435),
MDA-MB-231 (231), MDA-MB-435 expressing BRMS1 (435BRMS1) and MDA-MB-231
expressing BRMS1 (231BRMS1) were described previously [21]. Cell culture media and
supplies were purchased from Thermo Fisher Scientific Inc. (Waltham, MA). Other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO) at the highest available
purity.
3.3.2 Instrumentation
The morphology of the gold nanorods (AuNRs) SERS probe was determined by a
FEI Titan 80-300 transmission electron microscope (TEM) in a bright-field mode.
Extinction spectra of the AuNRs were taken by an Agilent Cary 60 UV-Vis
Spectrophotometer controlled by Cary WinUV software. Dark field images of cell samples
were obtained by using an Olympus IX71 Inverted Microscope equipped with an oilimmersed dark field condenser (NA=1.5) and a 100 objective lens. Images were acquired
using DPController software (Olympus).
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3.3.3 Preparation of SERS probe
As shown in Figure 3.1a, the synthesis of the SERS probe includes three steps: (1)
bare AuNRs and Raman reporter molecules 4-mercaptobenzoic acid (MBA) were mixed
together with a molar ratio of 1:10000, conjugating the reporter molecules onto AuNRs
through Au-S interaction; (2) polyallylamine hydrochloride (PAH) solution (28 mg mL-1,
200 µL) and NaCl solution (1 mM, 100 µL) were added to 1 mL of AuNRs solution
containing 1 nM MBA-AuNRs and reacted for 3 hr; and (3) after removing the excess PAH
by centrifugation, monoclonal antibody anti-EGFR (0.21 mg mL-1, 10 µL) was added to
the solution and incubated for 1 hr. Excess antibody was removed by centrifugation. The
SERS probe was stable for several days at 4°C in solution.
3.3.4 Cell culture
Cell lines were grown in a mixture of Dulbecco’s-modified Eagle’s medium
(DMEM) and Ham’s F-12 medium (1:1) supplemented with 5% fetal bovine serum
(Atlanta Biologicals, Atlanta, GA) in a humidified atmosphere at 37°C with 5% CO2. Cells
were at 80~90% confluence when used for experiments.
3.3.5 Immunoblotting
Cells were rinsed twice with ice-cold PBS and lysed in a buffer containing 25 mM
Tris-HCl (pH 7.4), ß-glycerol phosphate (50 mM), EDTA (0.5 mM), glycerol (5%), triton
X-100 (0.1%), sodium orthovanadate (1 mM), benzamidine (1 mM), and a protease
inhibitor cocktail containing aprotinin, leupeptin, and phenylmethylsulfonyl fluoride
(Roche, Indianapolis, IN). Protein concentration was determined using a BCA assay
(Pierce, Rockford, IL). Protein was denatured with Laemmli’s buffer at 95°C for 5 min and
lysate (50 μg) was loaded to each well. Proteins were separated using 10% SDS-PAGE gel
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electrophoresis and resolved proteins were transferred to PVDF before incubating in Trisbuffered saline containing Tween-20 (0.05%) and fat-free dry milk (5%) for 1 hr at room
temperature. Membranes were incubated with primary antibodies to EGFR (Cell Signaling,
Danvers, MA) β-Actin (Sigma, St. Louis, MO) and BRMS1 overnight at 4°C and
subsequently with HRP-conjugated secondary antibody at room temperature for 1 hr.
Signals were visualized using ECL (Pierce, Rockford, IL) following manufacturer’s
instructions.
3.3.6 Immunofluorescence imaging
To evaluate EGFR localization, MDA-MB-435/231 and 435BRMS1/231BRMS1 cells
grown on coverslips for 24 hr were fixed using 4% para-formaldehyde (Electron
Microscopy Sciences, Hatfield, PA) for 20 min, and permeabilized using 0.1% Triton X100 (Union Carbide Corporation, Texas City, TX) for 10 min. After blocking with 5% BSA
in PBS, cells were incubated with anti-EGFR antibody conjugated with Alexia Fluor 555
at 1:50 dilution (Life technologies, Carlsbad, CA) in 5% BSA solution overnight at 4°C.
After washing the cells thrice with PBS, the cover slips were mounted using Vectashield
mounting solution containing the nuclear counter-stain 4′, 6-diamidino-2-phenylindole
(Vector laboratories Inc, Burlingame, CA). Images were collected under a Nikon inverted
epifluorescence microscope. Representative images were combined, and processed using
ImageJ software.
3.3.7 SERS measurement on living cancer cells
Cells were used at a density of 0.5  105 cells per milliliter. Media (2 mL)
containing cells were placed on a cleaned magnesium fluoride (MgF2) optical window
(United Crystals Co., Port Washington, NY) in order to minimize background in Raman
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measurement. Cells cultured on MgF2 were incubated with the antibody conjugated SERS
probes for different time (1.5, 3, 4.5 and 6 hr) and washed with PBS to remove nonadsorbed probes prior to Raman measurements.
Raman spectra were measured by a Renishaw inVia Raman system (controlled by
WiRE 3.3 software, Renishaw, UK) connected to a Leica microscope (Leica DMLM, Leica
microsystems, USA) equipped with a 785 nm near-IR laser that was focused through a 63
water immersion objective (NA=0.90, Leica Microsystems). The instrument was calibrated
with silicon (Raman peak centered at 520.5 cm-1). Raman spectra (600 and 1800 cm-1) were
recorded using 1 accumulation per 10 sec laser exposure (1% laser intensity (3 mW) static
mode). For Raman line and depth profiling, multiple spectra were acquired at different
locations with constant intervals (line: 3 µm; depth: 1.5 µm). Spectral smoothing, baseline
subtraction and Raman mapping generation were performed using Renishaw WiRE 3.3
software. The processed spectra were exported to Origin Pro 8.5 software (OriginLab Corp.,
USA) for statistical analysis.
3.3.8 Cell viability test
The cell viability was analyzed using LIVE/DEAD Viability/Cytotoxicity Assay
Kit (Invitrogen) according to the manufacturer’s instruction. Briefly, (1) cells were cultured
in poly-D-lysine coated glass-bottom dishes (MatTek Cop. USA) and MgF2 substrate
which was put in Petri dishes for 24 hr; (2) cells were then washed with PBS twice; (3) 2
ml of mixed solution of 2 µM Calcein AM and 4 µM ethidium homodimer-1 (EthD-1)
(both from Invitrogen) was added directly to cells, and incubated cells for 30 min at room
temperature; (5) cells were imaged using fluorescence microscope with DP30BW CCD
camera (Olympus IX71) to analyze the relative proportion of live/dead cells. Here, a 10×

64
objective was used to observe fluorescence. Calcein AM is well retained within live cells
producing green fluorescence; however, EthD-1 enters cells with damaged membrane and
binds to nucleic acids, thereby producing a red fluorescence in dead or membrane-damaged
cells. Therefore, the live/dead cells were differentiated visually.
3.4 RESULTS AND DISCUSSION
3.4.1 Characterization of the SERS probe
Figure 3.1a illustrates preparation of the MBA-encoded, PAH-coated, and antiEGFR functionalized AuNRs as the SERS probes. The size and morphology of the SERS
probes were visualized by TEM (Figure 3.1b). The successful coating of PAH and antibody
was confirmed by a thin dim film on the surface of AuNRs and the slight red-shift of the
maximum plasmon peaks (Figure 3.1c). MBA was used as a Raman reporter molecule to
optimize SERS sensitivity due to its strong affinity to Au surface and simple SERS
spectrum. The PAH molecule, a polyelectrolyte with positive charge, plays an important
role by, not only preventing AuNR aggregation, but also providing biocompatibility to the
SERS probes (Figure 3.2). Compared with other polymer coatings, such as thiol-PEG and
silica, polyelectrolyte coating simplified the process, and more importantly, avoided
adsorption competition with Raman reporters [14, 28]. Taken together, these conditions
were expected to provide higher SERS sensitivity.
Figure 3.1c shows the stepwise extinction spectra of the AuNR during the
preparation process. The longitudinal plasmon resonance band for bare AuNR is located at
ca. 770 nm, which is related to the 3.7 aspect ratio of the nanorods (Figure 3.1b). The
nanorod longitudinal plasmon band (770 nm) is favorable in this work because it overlaps,
in part, with the excitation laser source (785 nm), providing >10 surface enhancement
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than substrates whose Plasmon bands do not overlap with the excitation source [29]. After
coating with MBA, PAH and antibody, the longitudinal plasmon band maxima red-shifted
5 nm, which is thought to be due to changes in local refractive index. Red shifts were also
reported previously [14, 30, 31]. A typical SERS spectrum of the MBA-linked SERS probe
is shown in Figure 3.1d. The two highest Raman peaks (1077 and 1588 cm-1) were observed
and could be assigned to the ring breathing and axial deformation modes of MBA,
respectively [32, 33]. Since the peak at 1077 cm-1 was the most stable and reproducible
characteristic band for the reporter, MBA, it was used for further Raman analysis in this
study.
3.4.2 Detection of EGFR on single A431 cells
SERS has been widely applied since 1970s when it’s reported that molecular
adsorption onto a roughened noble metal surface led to electromagnetic and chemical
enhancement mechanisms [34, 35]. Using a molecule with an intense and distinguishable
Raman signature as a reporter molecule for sensing and quantification is called extrinsic
SERS (reviewed in [36]). In the presented work, the extrinsic SERS strategy is used—we
are trying to detect cell surface receptor EGFR using anti-EGFR antibody targeted SERS
nanoprobes, conjugated with MBA as reporter molecule, and track the EGFR localization
by measuring the specific Raman signature of MBA.
In order to investigate whether the anti-EGFR functionalized SERS probe can
successfully detect the expression of EGFR on cells, A431, which highly expresses EGFR
[37-39], was used (Figure 3.3). The SERS probe were incubated with A431 cells under
three different conditions: (1) cells were incubated with SERS probes without anti-EGFR
antibody conjugation for 1.5 hr at 37°C (“No Antibody”, representing non-specific
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interaction); (2) cells were incubated with anti-EGFR antibody-conjugated SERS probes
for 1.5 hr at 37°C (“Antibody”); (3) cells were pre-blocked with free anti-EGFR antibody
for 1 hr before incubation with the antibody-conjugated SERS probe for 1.5 hr
(“Antibody_Block”). Typical SERS spectra for the three groups are shown in Figure 3.3a.
“Antibody group” shows two major intense peaks at 1077 cm-1 and 1588 cm-1, while the
peak intensities are very low in “No Antibody” group and “Antibody_Block” group. The
Raman intensities at 1077 cm-1 for “Antibody” group was significantly higher (P<0.001,
n=60) than the other two treatment groups (Figure 3.3b), demonstrating the specificity of
the antibody-antigen interaction. SERS mapping images revealed intense signals in
“Antibody” group but significantly less in the other two conditions (Figure 3.3c). Thus, the
findings confirm that SERS specifically recognizes EGFR on A431 cells by antibodyantigen interactions.
3.4.3 Local distribution and depth profiling of EGFR on single A431 cells
The spatial distribution of EGFR on single A431 cell surface was also studied.
Figure 3.4 shows the Raman line profiling spectra when the laser spot was scanning over
different locations on a single A431 cell. Eleven separated locations across the cell were
measured along a straight line (Figure 3.4a). Only at central locations (# 4~7) were there
distinguishable SERS bands (Figure 3.4b). Figure 3.4c shows normalized SERS intensity
at 1077 cm-1 at all 11 points on the cell surface. This Raman line profiling shows that EGFR
markers were not homogeneously distributed on the cell surface, and seem mainly located
on the central region of the cell surface of this selected cell. This kind of EGFR distribution
had also been reported in some other studies, especially when EGF had been introduced
[40, 41].
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To study antibody-functionalized gold nanoparticles are internalized via receptormediated endocytosis [42, 43], a confocal Raman setting was applied to detect the SERS
spectra collected at depth levels ranging from 0 (top, upper cell surface), 3 μm (middle,
middle surface of the cell), to 6 μm (bottom, lower surface of the cell) (Figure 3.5). At 3hr incubation of the SERS probes with A431 cells, Raman streamline mapping (at 1077
cm-1) of the same cells at three different depths (0, 3, and 6 μm) were captured sequentially
(Figure 3.5a). Red areas in the mapping images represent the presence of the EGFR
molecules in single A431 cells. Raman spectra at an EGFR aggregate at different depths
(points 1-3, Figure 3.5a) are shown in Figure 3.5b. It shows the highest peak intensity at
the apical surface and lowest at the basal cell membrane, indicating that majority of the
AuNRs has still yet to be internalized at 3-hr incubation. To further study the EGFRmediated endocytosis of nanoparticle, we measured the Raman peak intensities at EGFR
aggregates at top, middle and bottom of the cells with 1.5 hr, 3 hr, 4.5 hr and 6 hr incubation
of SERS probes. As shown in Figure 3.5c, at 1-3 hr incubation, the highest peak intensities
are at the top surface of the cells, indicating that the internalization level is low; while at 46 hr incubation, the highest intensities are at the middle, which means most of the AuNRs
are internalized into the cells. As reported, the process of EGFR mediated endocytosis is
strongly influenced by the applied targeting ligands [44]. Here we used monoclonal
antibody as the targeting ligand, which is much slower than the EGF targeted EGFR
endocytosis [34]. This is because EGF can activate the receptor signaling, whereas the
antibody binding is unable to lead to considerable downstream receptor activation.
Fluorescence live/dead imaging test was conducted to prove that cells remained high
viability (>95 %) after incubation with SERS probes for 1.5, 3, 4.5 and 6 hr (Figure 3.2).
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3.4.4 BRMS1-regulated EGFR expression on MDA-MB-435 and MDA-MB-231
breast cancer cells
EGFR was significantly down-regulated in BRMS1-expressing human breast
cancer cell lines as previously reported [21]. In this report, the immunoblotting results
showed that reduction of EGFR in 231BRMS1 cells was not as dramatic as previously
reported. Nonetheless, the complete loss of EGFR in 435BRMS1 cells was readily apparent
by immunoblotting (Figure 3.6a). Using SERS probe to measure EGFR (Figure 3.6b),
435BRMS1 cells have significantly (P<0.001, n=60) lower levels than parental 435 cells. The
results are not significantly different when comparing 231 and 231BRMS1 cells (P>0.05,
n=60). The SERS results are essentially consistent with traditional western blot data
(Figure 3.6a). However, SERS mapping provides the spatial distribution of EGFR at the
single cell level that western blot does not have.
Dark-field microscopic imaging was also done (Figure 3.6c-f) since AuNR scatter
light intensely and they are much brighter than cells in the dark field [45, 46]. The presence
of many bright spots on 435 cells (Figure3.6c) reflects abundant EGFR expressed, while
the abundance of spots is negligible on 435BRSM1 cells (Figure 3.6d). The numbers of bright
spots in 231 cells are not readily distinguishable than those observed in 231BRMS1 cells,
consistent with the western blot results. Based on the dark field images and SERS spectra
in living cells, the constructed SERS probes can be utilized as multimodal cell imaging
sensors.
Recognition of EGFR molecules and analysis of their distribution on single cells
was done by SERS mapping at 1077 cm-1 comparing 231 and 435 cells with their BRMS1expressing counterparts (Figure 3.7). Bright field images (upper panel) and their
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corresponding SERS maps (lower panel) were simultaneously recorded. EGFR was
heterogeneously distributed on the plasma membrane. To further validate the observations
from SERS method, 435, 231, 435BRMS1 and 231BRMS1 cells were labeled with anti-EGFR
antibody conjugated to Alexia Fluor 555 to measure EGFR localization using
immunofluorescence (IF) imaging. As presented in Figure 3.8, the IF images confirmed
the down-regulation of EGFR expression by BRMS1 gene in MDA-MB-435 and MDAMB-231 cells as our SERS results suggested. The consistency between SERS and IF
results indicates SERS is a tool as powerful as IF to detect cellular receptors as single-cell
level. Moreover, SERS possesses potential advantages over fluorescence in multiplex
imaging of cell receptors due to much narrower spectroscopic bands of Raman spectra.
3.5 CONCLUSIONS
We developed a AuNR-based SERS probe that allows live-cell targeting and
imaging of EGFR, a widely recognized breast cancer marker. The probe successfully
detected EGFR and distinguished heterogeneity in its distribution on the plasma membrane
of cells growing in culture. Furthermore, using Raman depth mapping, internalization of
the SERS probes could be monitored temporally and spatially. Data using the SERS probes
are consistent with standard detection methods, but affords the capability to measure
dynamic changes molecules in living cells. Thus, our SERS probes can be used as a
noninvasive sensing agent for detection of spatial distribution and dynamic change of
EGFR on living breast cancer cells at the single cell level, which is a significantly
complement to the traditional biochemical approaches like immunoblotting and
immunofluorescence. This work also demonstrated the potential of using SERS to
investigate EGFR-involved physiological process such as EGFR-mediated nanoparticle
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uptake and EGF-EGFR interaction. Our future work is to study multiple cell surface
receptors and their interactions by using different Raman reporter labeling; besides, using
tip-enhanced Raman Spectroscopy (TERS) would be alternative option allowing us to
achieve single-molecular detection of cell receptors at nanoscale cell surface.
3.6 REFERENCES
[1] H. Masuda, D.W. Zhang, C. Bartholomeusz, H. Doihara, G.N. Hortobagyi, N.T. Ueno,
Role of epidermal growth factor receptor in breast cancer, Breast Cancer. Res. Tr. 136
(2012) 331-345.
[2] J.R.C. Sainsbury, J.R. Farndon, G.K. Needham, A.J. Malcolm, A.L. Harris, Epidermalgrowth factor receptor status as predictor of early recurrence of and death from breast
cancer, Lancet 1 (1987) 1398-1402.
[3] V. Grunwald, M. Hidalgo, Developing inhibitors of the epidermal growth factor
receptor for cancer treatment, J. Natl. Cancer I. 95 (2003) 851-867.
[4] G. Chen, P. Kronenberger, E. Teugels, I.A. Umelo, J. De Greve, Targeting the
epidermal growth factor receptor in non-small cell lung cancer cells: the effect of
combining RNA interference with tyrosine kinase inhibitors or cetuximab, BMC Med. 10
(2012) 28.
[5] S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, A. Bardelli, Biomarkers
predicting clinical outcome of epidermal growth factor receptor-targeted therapy in
metastatic colorectal cancer, J. Natl. Cancer I. 101 (2009) 1308-1324.
[6] S. Muller, L. Su, M. Tighiouart, N. Saba, H.Z. Zhang, D.M. Shin, Z. Chen, Distinctive
E-cadherin and epidermal growth factor receptor expression in metastatic and

71
nonmetastatic head and neck squamous cell carcinoma—predictive and prognostic
correlation, Cancer-Am. Cancer Soc. 113 (2008) 97-107.
[7] A. Psyrri, M. Kassar, Z.W. Yu, A. Bamias, P.M. Weinberger, S. Markakis, D. Kowalski,
R.L. Camp, D.L. Rimm, M.A. Dimopoulos, Effect of epidermal growth factor receptor
expression level on survival in patients with epithelial ovarian cancer, Clin. Cancer Res.
11 (2005) 8637-8643.
[8] X.Q. Yang, C. Chen, C.W. Peng, J.X. Hou, S.P. Liu, C.B. Qi, Y.P. Gong, X.B. Zhu,
D.W. Pang, Y. Li, Quantum dot-based quantitative immunofluorescence detection and
spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays, Int. J.
Nanomed. 6 (2011) 2265-2273.
[9] J. Kneipp, H. Kneipp, K. Kneipp, SERS—a single-molecule and nanoscale tool for
bioanalytics, Chem. Soc. Rev. 37 (2008) 1052-1060.
[10] R.A. Alvarez-Puebla, L.M. Liz-Marzan, SERS-based diagnosis and biodetection,
Small 6 (2010) 604-610.
[11] K.K. Maiti, U.S. Dinish, C.Y. Fu, J.J. Lee, K.S. Soh, S.W. Yun, R. Bhuvaneswari, M.
Olivo, Y.T. Chang, Development of biocompatible SERS nanotag with increased stability
by chemisorption of reporter molecule for in vivo cancer detection, Biosens. Bioelectron.
26 (2010) 398-403.
[12] G. von Maltzahn, A. Centrone, J.H. Park, R. Ramanathan, M.J. Sailor, T.A. Hatton,
S.N. Bhatia, SERS-coded gold nanorods as a multifunctional platform for densely
multiplexed near-infrared imaging and photothermal heating, Adv. Mater. 21 (2009) 31753180.

72
[13] C.L. Zavaleta, B.R. Smith, I. Walton, W. Doering, G. Davis, B. Shojaei, M.J. Natan,
S.S. Gambhir, Multiplexed imaging of surface enhanced Raman scattering nanotags in
living mice using noninvasive Raman spectroscopy, Proc. Natl. Acad. Sci. USA 106 (2009)
13511-13516.
[14] L. Jiang, J. Qian, F.H. Cai, S.L. He, Raman reporter-coated gold nanorods and their
applications in multimodal optical imaging of cancer cells, Anal. Bioanal. Chem. 400
(2011) 2793-2800.
[15] X.M. Qian, X.H. Peng, D.O. Ansari, Q. Yin-Goen, G.Z. Chen, D.M. Shin, L. Yang,
A.N. Young, M.D. Wang, S.M. Nie, In vivo tumor targeting and spectroscopic detection
with surface-enhanced Raman nanoparticle tags, Nat. Biotechnol. 26 (2008) 83-90.
[16] D.C. Kennedy, D.R. Duguay, L.L. Tay, D.S. Richeson, J.P. Pezacki, SERS detection
and boron delivery to cancer cells using carborane labelled nanoparticles, Chem. Commun.
(2009) 6750-6752.
[17] P. Wu, Y. Gao, H. Zhang, C.X. Cai, Aptamer-guided silver-gold bimetallic
nanostructures with highly active surface-enhanced Raman scattering for specific detection
and near-infrared photothermal therapy of human breast cancer cells, Anal. Chem. 84
(2012) 7692-7699.
[18] J. Yang, Z.Y. Wang, S.F. Zong, C.Y. Song, R.H. Zhang, Y.P. Cui, Distinguishing
breast cancer cells using surface-enhanced Raman scattering, Anal. Bioanal. Chem. 402
(2012) 1093-1100.
[19] X. Wang, X.M. Qian, J.J. Beitler, Z.G. Chen, F.R. Khuri, M.M. Lewis, H.J.C. Shin,
S.M. Nie, D.M. Shin, Detection of circulating tumor cells in human peripheral blood using
surface-enhanced Raman scattering nanoparticles, Cancer Res. 71 (2011) 1526-1532.

73
[20] S.A. Eccles, D.R. Welch, Metastasis: recent discoveries and novel treatment strategies,
Lancet 369 (2007) 1742-1757.
[21] K.S. Vaidya, S. Harihar, P.A. Phadke, L.J. Stafford, D.R. Hurst, D.G. Hicks, G. Casey,
D.B. DeWald, D.R. Welch, Breast cancer metastasis suppressor-1 differentially modulates
growth factor signaling, J. Biol. Chem. 283 (2008) 28354-28360.
[22] R.S. Samant, D.W. Clark, R.A. Fillmore, M. Cicek, B.J. Metge, K.H. Chandramouli,
A.F. Chambers, G. Casey, D.R. Welch, L.A. Shevde, Breast cancer metastasis suppressor
1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappa B activation, Mol.
Cancer 6 (2007) 6.
[23] D.B. DeWald, J. Torabinejad, R.S. Samant, D. Johnston, N. Erin, J.C. Shope, Y. Xie,
D.R. Welch, Metastasis suppression by breast cancer metastasis suppressor 1 involves
reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells, Cancer
Res. 65 (2005) 713-717.
[24] M. Cicek, R. Fukuyama, D.R. Welch, N. Sizemore, G. Casey, Breast cancer metastasis
suppressor 1 inhibits gene expression by targeting nuclear factor-kappa B activity, Cancer
Res. 65 (2005) 3586-3595.
[25] T.M. Bodenstine, K.S. Vaidya, A. Ismail, B.H. Beck, L.M. Cook, A.R. Diers, A.
Landar, D.R. Welch, Homotypic gap junctional communication associated with metastasis
suppression increases with PKA activity and is unaffected by PI3K inhibition, Cancer Res.
70 (2010) 10002-10011.
[26] M.M. Saunders, M.J. Seraj, Z.Y. Li, Z.Y. Zhou, C.R. Winter, D.R. Welch, H.J.
Donahue, Breast cancer metastatic potential correlates with a breakdown in homospecific

74
and heterospecific gap junctional intercellular communication, Cancer Res 61 (2001)
1765-1767.
[27] D.R. Hurst, D.R. Welch, Unraveling the enigmatic complexities of BRMS1-mediated
metastasis suppression, FEBS Lett. 585 (2011) 3185-3190.
[28] X.B. Tan, Z.Y. Wang, J. Yang, C.Y. Song, R.H. Zhang, Y.P. Cui,
Polyvinylpyrrolidone- (PVP-) coated silver aggregates for high performance surfaceenhanced Raman scattering in living cells, Nanotechnology 20 (2009) 445102.
[29] C.J. Orendorff, L. Gearheart, N.R. Jana, C.J. Murphy, Aspect ratio dependence on
surface enhanced Raman scattering using silver and gold nanorod substrates, Phys. Chem.
Chem. Phys. 8 (2006) 165-170.
[30] H. Ding, K.T. Yong, I. Roy, H.E. Pudavar, W.C. Law, E.J. Bergey, P.N. Prasad, Gold
nanorods coated with multilayer polyelectrolyte as contrast agents for multimodal imaging,
J. Phys. Chem. C 111 (2007) 12552-12557.
[31] A. Gole, C.J. Murphy, Polyelectrolyte-coated gold nanorods: Synthesis,
characterization and immobilization, Chem. Mater. 17 (2005) 1325-1330.
[32] S.W. Bishnoi, C.J. Rozell, C.S. Levin, M.K. Gheith, B.R. Johnson, D.H. Johnson, N.J.
Halas, All-optical nanoscale pH meter, Nano Lett. 6 (2006) 1687-1692.
[33] A. Michota, J. Bukowska, Surface-enhanced Raman scattering (SERS) of 4mercaptobenzoic acid on silver and gold substrates, J. Raman Spectrosc. 34 (2003) 21-25.
[34] M.G. Albrecht, J.A. Creighton, Anomalously intense Raman-spectra of pyridine at a
slver electrode, J. Am. Chem. Soc. 99 (1977) 5215-5217.

75
[35] D.L. Jeanmaire, R.P. Van Duyne, Surface Raman spectroelectrochemistry: Part I.
heterocyclic, aromatic, and aliphatic amines adsorbed on the anodized silver electrode, J.
Electroanal. Chem. 84 (1977) 1-20.
[36] K.C. Bantz, A.F. Meyer, N.J. Wittenberg, H. Im, O. Kurtulus, S.H. Lee, N.C.
Lindquist, S.H. Oh, C.L. Haynes, Recent progress in SERS biosensing, Phys. Chem. Chem.
Phys. 13 (2011) 11551-11567.
[37] Z. Novy, P. Barta, J. Mandikova, M. Laznicek, F. Trejtnar, A comparison of in vitro
methods for determining the membrane receptor expression in cell lines, Nucl. Med. Biol.
39 (2012) 893-896.
[38] C. Linassier, M. Pierre, J.B. Lepecq, J. Pierre, Mechanisms of action in NIH-3T3 cells
of genistein, an inhibitor of EGF receptor tyrosine kinase activity, Biochem. Pharmacol.
39 (1990) 187-193.
[39] T. Akiyama, J. Ishida, S. Nakagawa, H. Ogawara, S. Watanabe, N. Itoh, M. Shibuya,
Y. Fukami, Genistein, a specific inhibitor of tyrosine-specific protein kinases, J. Biol.
Chem. 262 (1987) 5592-5595.
[40] J. Merlin, L. Stechly, S. de Beauce, D. Monte, E. Leteurtre, I. van Seuningen, G. Huet,
P. Pigny, Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR
downstream pathways in pancreatic cancer cells, Oncogene 30 (2011) 2514-2525.
[41] B.G. Bitler, A. Goverdhan, J.A. Schroeder, MUC1 regulates nuclear localization and
function of the epidermal growth factor receptor, J. Cell Sci. 123 (2010) 1716-1723.
[42] A.E. Nel, L. Madler, D. Velegol, T. Xia, E.M.V. Hoek, P. Somasundaran, F. Klaessig,
V. Castranova, M. Thompson, Understanding biophysicochemical interactions at the nanobio interface, Nat. Mater. 8 (2009) 543-557.

76
[43] I. Lynch, K.A. Dawson, Protein-nanoparticle interactions, Nano Today 3 (2008) 4047.
[44] F.M. Mickler, L. Mockl, N. Ruthardt, M. Ogris, E. Wagner, C. Brauchle, Tuning
nanoparticle uptake: live-cell imaging reveals two distinct endocytosis mechanisms
mediated by natural and artificial EGFR targeting ligand, Nano Lett 12 (2012) 3417-3423.
[45] X.H. Huang, I.H. El-Sayed, W. Qian, M.A. El-Sayed, Cancer cell imaging and
photothermal therapy in the near-infrared region by using gold nanorods, J. Am. Chem.
Soc. 128 (2006) 2115-2120.
[46] X.H. Huang, I.H. El-Sayed, W. Qian, M.A. El-Sayed, Cancer cells assemble and align
gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized
surface Raman spectra: a potential cancer diagnostic marker, Nano Lett. 7 (2007) 15911597.

77

Figure 3.1 (a) Schematic illustration of the fabrication of the gold nanorods-based,
antibody-functionalized SERS probe. (b-d) Characterizations of the SERS probe. (b) TEM
image of the bare AuNRs, scale bar is 50 nm. (c) Extinction spectra of the AuNRs at each
step of the coating process. (d) SERS spectrum of the antibody-functionalized AuNRs with
4-MBA as the reporter molecules. AuNR: gold nanorod; 4-MBA: 4-mercaptobenzoic acid.
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Figure 3.2 Fluorescence cell viability test. Cells were stained with Invitrogen LIVE/DEAD
Viability/Cytotoxicity Assay Kit. Green fluorescence presented live cells, whereas red
fluorescence showed dead or membrane-damaged cells. All images were obtained with
10× lens. The viability test shows that over 95% of A431 cells are alive after incubation
with SERS probes for 1.5, 3, 4.5 and 6 hr. Over 500 cells were counted for each of the
incubation times.
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Figure 3.3 Performance assessment of constructed SERS probe. (a) Typical SERS spectra,
(b) normalized average Raman intensities at 1077 cm-1 (curve numbers, n=60), and (c)
typical single-cell bright-field and corresponding SERS mapping images of A431 cells
incubated with (1) SERS probes without anti-EGFR antibody conjugation (No Antibody);
(2) anti-EGFR antibody-conjugated SERS probes (Antibody); (3) free anti-EGFR
antibody molecules prior to the incubation with antibody-conjugated SERS probes
(Antibody_Block). Raman spectral images were created by the selection of peak 1077 cm1

. The intensities were normalized between the lowest (0) and highest (1) color values.

Image size: 30  30 μm2. * P<0.001.
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Figure 3.4 Raman line profiling of SERS probes bind to single A431 cell surface. (a) Image
of an A431 cell showing 11 different locations with Raman measurements. (b) Raman
profiles of the 11 points shown in (a). (c) Normalized Raman intensities at 1077 cm -1 at
those eleven different locations.
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Figure 3.5 Raman depth profiling of SERS probes bound to single A431 cell surface. (a)
Raman streamline mapping (at 1077 cm-1) of a living A431 cell. Three images (top, middle,
and bottom) were respectively obtained at three different depths (0, 3 and 6 μm), when the
cells were incubated with the SERS probes for 3 hrs. (b) The typical SERS spectra
measured on the single cell shown in (a) at locations 1-3 with different depths. (c) Raman
intensities (1077 cm-1) at different depths with 1.5, 3, 4.5 and 6 hr incubation times, n=90,
Error bar: SE of mean. Image size: 52  39 μm2.
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Figure 3.6 Comparison of EGFR detection by (a) immunoblotting and (b) SERS probes on
MDA-MB-435 and MDA-MB-231 breast cancer cells, and their BRMS1 expressing cell
lines MDA-MB-435BRMS1 and MDA-MB-231BRMS1. (c-f) Dark field images of the SERS
probes on MDA-MB-435 and MDA-MB-231 cells with (c, e) and without (d, f) BRMS1
expression. * P<0.001. n = 60, number of spectra collected.
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Figure 3.7 Bright field and SERS mapping (1077 cm-1) images of four breast cancer cell
lines: 435, 435BRMS1, 231 and 231BRMS1. The intensities were normalized between the
lowest (0) and the highest (1) color values for each pair of 435 vs. 435BRMS1, and 231 vs.
231BRMS1. Mapping size for all images is 30  30 μm2.
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Figure 3.8 Immune-fluorescence images for showing the expression of EGFR in MDAMB-435, MDA-MB-435BRMS1, MDA-MB-231 and MDA-MB-231BRMS1 cells. First
column: EGFP; second column: EGFR; third column: nucleus; fourth column: merge of
first three columns.
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CHAPTER 4
SIMULTANEOUS TOPOGRAPHIC AND SINGLE MOLECULE
RECOGNITION IMAGING OF EPIDERMAL GROWTH FACTOR RECEPTOR
(EGFR) ON SINGLE HUMAN BREAST CANCER CELLS
4.1 ABSTRACT
Epidermal growth factor receptor (EGFR) plays an important role in signaling
pathway of the development of breast cancer cells. Since EGFR over expresses in most
breast cancer cells, it is regarded as a biomarker molecule of breast cancer cells. Here we
demonstrated a new AFM technique—topography and recognition imaging (TREC)—to
simultaneously obtain highly sensitive and specific single-molecule recognition images
and high-resolution topographic images of EGFR on single breast cancer cells.
4.2 INTRODUCTION
Epidermal growth factor receptor (EGFR) is a member of receptor tyrosine kinase
(RTK) family of signaling proteins. It was the first mammalian signaling protein to be fully
characterized [1]. The activation of EGFR is normally controlled by the interaction with
their ligands such as EGF and TGF-α, providing cells with substantial differentiation and
growth advantages [2]. However, it has been found that aberrant expression or activation
of EGFR appears to be an important factor in both the initiation and the progression of
human caner [3-5]. For example, in human breast carcinoma (EGFR positive), expression
of EGFR was reported to support the existence of tumor cells with aggressive potentials
[6]. The expression level of EGFR in metastatic breast tumors was often higher than
primary tumors, indicating that EGFR was involved in the process of metastasis [7, 8].
Overexpression and abnormal function of EGFR and its ligands have been found in many

86
different types of human cancers [5]; this makes it a great prognostic indicator for the
development of malignancies. Furthermore, therapeutic strategies have been developed,
using small biomolecules (e.g. monoclonal antibody, kinase inhibitors) to block the binding
of EGFR and its ligands, consequently blocking receptor activation and transduction of
post-receptor signals [9, 10].
Recent study has shown that EGFR functionality can be dependent on its
subcellular location and mislocated EGFR may regulate tumor response to therapy [11].
Therefore, localization of EGFR on cancer cells is of great importance. However, it is very
challenging to probe the spatial and temporal distribution of specific cell receptors and
their signaling-related molecular actions in molecular cell biology [12, 13]. In recent years,
sophisticated technologies have been developed to achieve the identification and
localization of those biomolecules in cells. Among them are (1) fluorescence imaging with
improved spatial resolution, which can offer the approach to monitor the dynamic
information about the localization, distribution of biomolecules and their cell-signaling
actions [14, 15]; (2) electron-dense probes and electron microscopy, which provide
nanometer resolution in characterizing and mapping membrane receptors and signaling
molecules [16]; (3) a combination of quantitative mass spectrometry and cryo-electron
tomography, providing insights into the distribution of specific protein complexes in
cytoplasm [17, 18]. Although these advanced technologies have significantly improved the
capability of detecting and localizing cell receptors, some limitations still remain: high
spatial and temporal resolution, the requirement of physiological and dynamic condition,
and the chemical specificity. Few techniques can overcome all these limitations and
provide critical measurements of cell membrane receptors.
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Since its invention in 1980s, atomic force microscopy (AFM) has become a
powerful tool technique for analyzing the morphology of individual molecules at
nanometer scale and the forces acting on them with piconewton sensitivity. As to the study
of biological samples, AFM presents significant advantages than other microscopic
methods since it allows single-molecule level studies of the structure and interaction of
complicated biomolecules and cells with nanometer spatial resolution [19], and it allows
samples to be measured in liquid phase, enabling the study of dynamic interactions between
biomolecules under physiological condition. Simultaneous Topography and RECognition
(TREC) imaging, a new AFM technique based on the high-resolution topographic imaging
and single-molecule force measurement [20, 21], has been developed for receptor imaging
with high spatial and temporal resolution, providing exceptional information that is
complementary to that obtained by fluorescence and electron microscopy [22]. For
example, TREC imaging has been successfully used to visualize, at the first time, the
localization and distribution of Na+-K+ ATPases in the inner leaflet of cell membranes at
single-molecule level [23]; by employing TREC, the local organization of Fcγ receptors
on single macrophage cell has been determined at single-molecule level [24]. In addition
to cell receptor imaging, TREC imaging technique has also been extensively used to
monitor specific biomolecules while they are undergoing biological processes. Wang et
al. [20, 25, 26] applied TREC to study the action of human Swi-Snf nucleosome
remodeling complex and its interaction with mouse mammary tumor virus promoter during
the process of nucleosome remodeling, proving the crucial role of ATP activation in the
process. Besides, they were also able to recognize the glycosylation process of
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biomolecules by using TREC imaging, and distinguish normal and aberrant antibodies
based on their glycosylation [27].
In this context, we applied TREC imaging method to detect and localize EGFR at
single molecule level. Single molecule recognition using monoclonal antibody (anti-EGFR)
tethered scanning tip was converted to high resolution Topography and Recognition images.
The recognition efficiency was tested in a spatio-temporal manner by introducing EGF as
a competing ligand, when conducting TREC imaging of EGFR using antibody-tethered
AFM tips. We measured the density and distribution of EGFR on breast cancer cell lines—
MDA-MB-435 (435) and 435 transfected with BRMS1 gene (BReast cancer Metastasis
Supressor 1 [28, 29], 435BRMS1). In addition, the advantages of TREC imaging over
conventional detection methods (e.g. immunofluorescence, western blot) have been
discussed.
4.3 MATERIALS AND METHODS
4.3.1 Sample preparation and cell culture
For TREC imaging on mica, epidermal growth factor receptor (EGFR, Life
Technologies, Grand Island, NY) solution (21μg/ml, in 0.1X PBS) was dropped onto newly
pealed mica surface and left 10min for adsorption. Rinse several times with DI water to
wash away incompletely adsorbed EGFR and then load mica onto sample plate for
recognition imaging.
435 and 435BRMS1 cells were measured. 435BRMS1 cells were transfected with a
lentiviral vector construct expressing full length BRMS1 cDNA under the control of a
cytomegalovirus promoter [30]. 435 and 435BRMS1 cells were cultured in a 1:1 mixture of
Dulbecco’s-modified eagle’s medium (DMEM) and Ham’s F-12 medium supplemented
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with 5% fetal bovine serum (Hyclone, Logan, UT). Cells were cultured in 25-cm2 corning
tissue culture dishes at 37 ℃ with 5% CO2 in a humidified atmosphere. Cells were
passaged at 80–90% confluence using 2 mM EDTA in Ca2+/Mg2-free PBS (PBS, 0.01 M,
pH 7.4, Thermo Scientific). Cell lines were confirmed to be free of mycoplasma
contamination using PCR (TaKaRa-Clontech, Mountain View, CA). No antibiotics or
antimycotics were used during routine culture. For TREC imaging on cell surface, cells
were fixed with paraformaldehyde and measured in PBS buffer.
4.3.2 AFM tip functionalization
Magnetically coated silicon-nitride AFM tips (Type VI MAC Levers, Agilent
Technologies, Chandler, AZ) were functionalized with anti-EGFR antibody using the
method reported previously [20]. Briefly, MAC levers were first amino-functionalized with
APTES (aminopropyltriethoxysilane, Sigma-Aldrich, St. Louis, MO) under the
atmosphere of argon. Subsequently, after rinsing with methylene chloride (Sigma-Aldrich)
for 3 times, MAC levers were attached to NHS-PEG-SS-Pyr (PolyPure, Oslo, Norway) by
incubating the tips with the PEG linker for 2hr, with the presence of triethylamine. At the
same time, monoclonal antibody to EGFR (anti-EGFR, Life Technologies, Grand Island,
NY) was thiolated by reacting with with N-cuccinimidyl 3-(acetylthio) propionate (SATP,
Sigma-Aldrich) and subsequently purified in a PD-10 column (GE Healthcare). Finally,
the thiolated antibody was conjugated to the AFM tip via the PEG crosslinker by 1h
incubation in deacetylation buffer (hydroxylamine hydrochloride and Triz Base, Sigma
Aldrich). Antibody functionalized MAC levers were then rinsed with PBS buffer and
stored in 4 ℃ before use.
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4.3.3 AFM recognition imaging
AFM recognition imaging was performed on a PicoPlus AFM system with a
commercially available electronic attachment (PicoTREC, Agilent Technologies).
Topography and recognition images were recorded simultaneously by using functionalized
MAC levers with nominal spring constant of 0.292 N/m. During TREC measurement, a
half-amplitude feedback loop was used to measure the unbiased topography. Eight to ten
nm free oscillation amplitude and ~20 kHz driving frequency of the tips were chosen to
obtain optimized recognition images. All these parameters were set to make the TREC
measurements more easy, robust and reliable [31]. Image processes (including smooth,
contrast adjustment) and the height and width measurements of tested proteins were
performed using PicoView software (Agilent Technologies).
The single cell AFM images were taken under contact mode with the instrument
setting exactly the same as previously described [32, 33].
4.3.4 Image processing
We employ an adaptive threshold-based segmentation method to find white spots
in a topological image and dark spots in a recognition image. We first convert the original
color image to a grayscale image. For the recognition image, we also invert its intensity
so the darkest spot turns to the brightest spot and vice versa. After this processing, we aim
to separately find white spots in the grayscale image of the topological image and the
inverted grayscale image of the recognition image. To this end, we first compute the
average intensity and the standard deviation of the grayscale image. The threshold is then
computed as the sum of the average intensity and the standard deviation. For the
topological image, we simply mark any position with the pixel intensity larger than the
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threshold as the white spot. For the recognition image, we similarly mark any position
with the pixel intensity larger than the threshold as the dark spot due to the inversion
process. Finally, we apply a logical "AND" operation to find the common areas shown up
in both white spots of the topological image and dark spots of its paired recognition
image. These areas are then overlaid on top of the original topological image to show the
white spots in topological image that have been simultaneously recognized in the
recognition image as the dark spots.
We implemented the image segmentation method using Matlab 2012(b).
4.4 RESULTS
4.4.1 Functionalization and SEM characterization of AFM MAC lever
Functionalization of AFM MAC Lever tips with anti-EGFR antibody was the key
point to achieve successful TREC measurements. As shown in Figure 4.1a, a procedure
with 4 steps involved has been implemented to conjugate anti-EGFR monoclonal antibody
with AFM tip to construct an EGFR-specific AFM nanosensor tip. It should be noted that,
in this method, a PEG chain was applied to link the tip and the antibody due to its flexibility
that allows for reorientation of the sensor molecule when the tip approaches the surface
[34, 35]. The free oscillation amplitude was set comparable to the extended length of the
PEG linker (~8nm) so that antibody on the tip remained bounding to the antigen on the
surface during imaging and kept high lateral accuracy as well [35]. The morphologies of
bare MAC Lever tip (Figure 4.1b) and anti-EGFR antibodies modified tip (Figure 4.1c)
were characterized by scanning electron microscope (SEM). It is clearly seen that the
morphology of modified probe was different from bare probe with the presence of “bumps”
or “clusters” on the surface.
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4.4.2 Specificity, Efficiency and Reproducibility of TREC
To evaluate the feasibility and efficiency of this TREC imaging method, we first
chose mica as the substrate, since it’s flat at atomic level and its much simpler
circumstances than cell membrane surface. EGFR molecules were adsorbed onto the mica
surface through electrostatic interaction. When anti-EGFR antibody-tethered AFM tip
approached the surface and scanned through the surface, antibody-antigen recognition
events occurred, simultaneously generating maps of the surface topography (Figure 4.2a)
and recognition (Figure 4.2b) signals. “Bright spots” on Figure 4.2a represent single
molecules or aggregates of EGFR, and the corresponding “dark spots” on Figure 4.2b
represent the recognition events of EGFR. These events were originated from the tiptethered antibody binds to antigens, restricting the tip to oscillate upwards and leading to
the reduction of the oscillation amplitude. To test the specificity of the recognition process,
an anti-EGFR solution (20 μg/mL) was injected via a liquid flow cell to block the
interaction between tip-tethered anti-EGFR and EGFR on the surface. After 10 min
adsorption, “dark spots” on recognition image were disappeared when conducting scan on
the same location (Figure 4.2c). Cross section analysis along the recognition events (green
lines on Figure 4.2a, b, and c) showed that before free anti-EGFR blocking, there were
significant recognition signals (Figure 4.2e) corresponding to the topography signals
(Figure 4.2d), which indicated the height of molecules on the surface; however, as blocked
by excess specific antibody, recognition signals of the antigens were dramatically
decreased (Figure 4.2f). Furthermore, as a control experiment, bare tip was employed to
scan EGFR on mica surface (Figure 4.3a). Apparent features on topography image were
presented, while no features were shown on recognition image. After a BSA solution (50
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μg/mL) was injected and let adsorbed for 10 min, recognition events still appeared as
antibody-tethered tip scanning on the surface (Figure 4.3b), showing that non-specific
protein-protein interaction wouldn’t affect the recognition. All these results indicate the
recognition events were highly specific—only EGFR molecules were recognized when
sensing with anti-EGFR antibody-tethered AFM tip.
Efficiency of the EGFR recognition was also tested on mica. As shown in Figure
4.4, bright spots in topography image and dark spots in recognition image were labeled by
a pair of green dots, representing a pair of recognition events took place. In this typical
image, almost all features (45 out of 47) in topography image were recognized, indicating
perfect recognition efficiency of this TREC imaging method to detect EGFR through
specific antibody-antigen interaction. In addition, to test the reproducibility of recognition,
the sample was rescanned at the same position. Only a few changes labeled with blue dots
and circles had happened in the rescan of the same area, showing generally high
reproducibility of the recognition.
4.4.3 EGF effects on TREC imaging of EGFR
EGF acts as a competing ligand that may affect the recognition of EGFR by AFM
tip-tethered anti-EGFR. To investigate how EGF affects the antibody-antigen recognition
between EGFR and its antibody, we applied TREC imaging to measure EGFR on mica
with and without EGF presence. As shown in Figure 4.5, when EGFR was presented alone
on the mica surface (Figure 4.5a), the recognition events (green) occurred at the most of
the “bright spots” area, indicating the high recognition efficiency between the tip-tethered
antibody and the EGFR; however, the TREC image scanned at 10 min after EGF (20 μg/mL)
introduction (Figure 4.5b) showed only reduced level of recognition, revealing the
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incomplete blocking by EGF on the binding sites between EGFR and its antibody.
Analyses of multiple images show that the average recognition percentage dropped from
84.3% to 57.4% when EGF is presented as a competitor (Figure 4.5c). Comparing the
partial block by EGF with the complete block by anti-EGFR antibody (Figure 4.2c), it is
suggested that the binding affinity to EGFR is higher for anti-EGFR antibody than for EGF.
4.4.4 TREC Imaging of EGFR on 435 and 435BRMS1 cells
Morphologies of single 435 and 435BRMS1 cells were visualized by contact mode
AFM, and they have been shown to be very different (Figure 4.6a-d). Typical topography
and deflection images of 435 cells are shown in Figure 4.6a and c. The shape of 435 cells
was observed to be round-like and the nucleic area possessed the most part of cell, which
is typical for cancer cells. Nevertheless, as shown in Figure 4.6b and d, the 435BRMS1 cell
has an elongated morphology and nucleus is smaller comparing with the 435 cell. Changes
in cell morphology caused by BRMS1 transfection has also been previously reported [36].
While features like chemosensitivity were not significantly affected by BRMS1 [37], the
BRMS1 did regulate the expression of several cellular receptors, such as EGFR [8, 38].
TREC imaging method was carried out to further probe the local distribution of
EGFR molecules on the membrane surface of 435 and 435BRMS1 cells. Comparing with the
TREC images on mica surface, the images on cells were less distinct with the distribution
of EGFR due to the complexity of cell membrane surface. We then applied an image
segmentation method to find out the corresponding “recognition sites” in topography and
recognition images, and superimpose the recognitions sites (green) onto corresponding
topography images (Figure 4.7a). The presence of recognition events were also confirmed
by the corresponding peaks occurred in the line profiles along the images (Figure 4.7b). It
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is found that EGFR heterogeneously distributed on 435 cells and tended to form domains
with a scale of a few nanometers (Figure 4.6e); with the expression of BRMS1, the numbers
of EGFR binding sites reduced and smaller domains were observed (Figure 4.6f). The
smallest “clusters” showing the recognition sites of EGFR molecules were nanometer scale,
which is comparative to the size of single molecule of EGFR, indicating that TREC is able
to achieve analysis of biomolecules at single-molecule level. Furthermore, the whole
imaging process was done within several min, which means TREC imaging is capable of
in situ monitoring many biological processes such as the activation of EGFR molecules by
their specific ligands (e.g. EGF, TGF-α).
4.5 DISCUSSION
4.5.1 BRMS1 role in EGFR regulation
It has been known that BRMS1 is a member of metastasis suppressors, which
inhibit metastasis without blocking orthotopic tumor formation in metastatic cascade [39,
40]. Previous studies have shown that the expression of BRMS1 in 435 cells regulates
biomechanical properties including cell adhesion and cell elasticity [36], which probably
induced by reorganization of cytoskeletal structures [41, 42]. Also, it has been reported that
BRSM1 regulates the expression of growth factor receptors in 435 cells by differentially
modulates their signaling pathway [8]. Aberrant EGFR signaling results in many
pathological diseases like neural developmental disorders and cancer [43]. Further, EGFR
signaling is mainly up-regulated in breast cancers through activation of NF-κB activity,
and BRMS1 has been shown to affect NF-κB activity [44, 45]. To probe this link, we
explored whether BRMS1 altered signaling through EGFR. Our previous work [38] has
confirmed that BRSM1 down-regulated the expression of EGFR in 435 breast carcinoma
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cells. However, up to now, there is no study reported the ability to obtain the information
about the local distribution of EGFR with nanoscale spatial resolution, which is necessary
to study the cellular biology of cell receptors, such as the interaction between receptors and
their specific ligands. TREC imaging presented high specificity, reproducibility and
recognition efficiency at nanoscale. Therefore, TREC imaging method has been applied in
order to identify the local binding sites of EGFR on single breast cancer cells.
4.5.2 Biological application of TREC imaging
Figure 4.8 briefly shows the principle of TREC imaging method. The basic
principle of TREC imaging is based on small alterations in cantilever oscillation amplitude
that occur when tip-tethered antibodies bind to their antigens. When the oscillating
antibody-tethered AFM tip scans through the sample, the tethered antibody binds to an
antigen on the surface and the upward oscillation of the cantilever is restricted by specific
antibody-antigen binding force, leading to the decrease in the oscillation amplitude. This
reduction of amplitude is sensed by the microscope servo and converted into reduction of
the recognition signal (peak voltages). Therefore, a map of recognition signals, together
with simultaneously generated topographic image, localizes the antibody-antigen binding
events with pairs of bright and dark spots showing on the image.
Applications of TREC technique in biomedical research is certainly an increasingly
demanding task. Up to now, TREC imaging method has been applied to visualize quite a
few different biomolecule systems, such as biotin-avidin [46, 47], ligand-receptor [48, 49],
and antibody-antigen interactions [20, 23]. In this study, we utilized TREC imaging to
visualize EGFR molecules on complex cell membrane surface, providing a new example
of the applications of this methodology in biomedical research. Due to the significant role
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of EGFR in cancer research, our work appears to inspire an alternative approach to primary
cancer diagnostics. Furthermore, TREC approach has the potential to study the dynamic
activation process of EGFR, which is of great significance, because EGFR can be activated
by its specific ligands (e.g. EGF, TGF-α), leading to the growth and spread of tumor [50].
Time resolution may be the concern. At present, it takes several min to record a recognition
image, which is more than enough for the activation and endocytosis of EGFR molecules.
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Figure 4.1 (a) Fabrication AFM MAC lever: (1) MAC lever amination; (2) link MAC lever
with PEG linker; (3) antibody activation by SATP; (4) SATP-antibody conjugate to AFM
tip. (b) SEM image for bare tip. (c) SEM image for anti-EGFR functionalized tip.

105

(a)

(d)

Topography (nm)

8
6
4
2
0
-2

0

50

100

150

200

EGFR

30

Recognition Signal (mV)

(b)

20
10
0
-10
-20
-30
-40

Mica

0

50

100

150

200

Distance (nm)

250

(f)

30

Recognition Signal (mV)

(c)

250

(e)

Distance (nm)

20
10
0
-10
-20
-30
-40

0

50

100

150

200

250

Distance (nm)

Figure 4.2 Specificity of recognition. (a) Topographic image and (b) corresponding
recognition image of EGFR on mica. (c) Recognition image of EGFR after blocking by
free anti-EGFR. (d, e, f) Cross section analysis along the green line in (a, b, c). Scan area:
500nm*500nm.
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Figure 4.3 Topographic image, corresponding recognition and cross section profile of
EGFR on mica under two conditions: (a) bare tip scans on EGFR only; (b) anti-EGFR
antibody-tethered tip scans on EGFR with BSA presence. Scan area: 500nm*500nm.
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Figure 4.4 Demonstration of recognition events. A pair of green dots in topography (a) and
corresponding recognition (b) images represents a recognition event. After rescanning at
the same location, changes in recognition events are labeled in the same recognition image
(b). Green dot surrounded by a blue circle means a recognition event appear in the first
scan but not in the second scan; blue dots represent recognition events appeared in the
second scan but not in the first scan. Scan area: 2000nm*2000nm.
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Figure 4.5 EGF influence on the recognition of EGFR on mica. Recognition events of
EGFRs (green) superimposed on corresponding topography images before (a) and 10 min
after (b) the introduction of EGF solution (20 μg/mL). (c) EGF effect on recognition
percentage.
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Figure 4.6 Single 435 and 435BRMS1 cells’ morphologies and their EGFR expression
measured by TREC. (a-d) are the topography images (a, b) and corresponding deflection
images (c, d) of Single 435 (a, c) and 435BRMS1 (b, d) cells. (e, f) are recognition events of
EGFRs (green) superimposed onto corresponding topography images of 435 (e) and
435BRMS1 cells (f).
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Figure 4.7 (a) Recognition image of EGFRs (green) superimposed on corresponding
topography images of 435 cell. (b) Cross section profile along the red line in (a).
Corresponding peaks were occurred at the positions of recognition sites, indicating the
recognition events.
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Figure 4.8 Schematic illustration of the TREC imaging method.
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CHAPTER 5
Gd2O3-DOPED SILICA @ GOLD NANOPARTICLES AS PROBES FOR IN
VITRO CANCER BIOMARKER IMAGING USING SURFACE-ENHANCED
RAMAN SPECTROSCOPY
5.1 ABSTRACT
Here we report a novel nanomaterial composed of gadolinium oxide-doped silica
nanoparticles and gold nanoparticles (Gd-Au NPs), which can be used for detection and
imaging of epidermal growth factor receptor (EGFR) on individual human cancer cells
with surface-enhanced Raman scattering (SERS). The Gd-Au NPs were sequentially
conjugated with a monoclonal antibody recognizing EGFR and a Raman reporter molecule,
4-meraptobenzoic acid (MBA), to generate characteristic SERS signal at 1075 cm-1. By
spatially mapping the SERS intensity at 1075 cm-1, cellular distribution of EGFR and
relocalization on the plasma membrane were measured. In addition, the EGFR expression
level in three human cancer cell lines (S18, A431 and A549) was measured using this SERS
probe, which was consistent with the comparable measurements using immunoblotting and
immunofluorescence.
5.2 INTRODUCTION
Noninvasive cancer imaging to exhibit tumor anatomical structure and to
investigate its metabolism plays an important role in early cancer detection and localization
[1]. Currently, there are several imaging modalities widely applied in cancer research, such
as magnetic resonance imaging (MRI) [2-5], photoacoustic (PA) imaging [6-8], surfaceenhanced Raman scattering (SERS) [9-11] and optical fluorescent imaging [12-15].
Although each individual modality has specific advantages in cancer imaging, none of
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them is able to support comprehensive structural and functional studies of tumors
independently. Thus, there has been an interest in developing multimodal approaches to
combine the advantages of these individual imaging modalities, as well as to compensate
for the weaknesses of individual imaging modalities. Recently, several composite
nanoparticles have been successfully synthesized and applied to multimodal imaging [1621]. These composite nanoparticles are usually constructed by combining together nanocomponents, which are effective contrast agents for different imaging modalities. For
example, Gao and co-workers [16] synthesized an iron oxide and gold-coupled core-shell
nanoparticles to integrate both MRI and PA imaging, which provided remarkable contrast
enhancement in bioimaging. Despite quickly growing interest in designing multifunctional
imaging contrast agents, the challenge remains to combine different imaging modalities
while preserving the controlled particle size.
Among varied imaging modalities, MRI has the advantages of high spatial and
temporal resolution and unlimited tissue penetration, which make it a great technique for
clinical diagnostics. But it also suffers the limitation of insufficient sensitivity and it is
unable to detect the subcellular distribution of the nanoscale contrast agent in living cancer
cells. In recent years, SERS has become an emerging non-invasive imaging tool in
detection of cancer cells and cancer biomarkers, due to its ultrahigh sensitivity and the
ability to reflect subtle changes in chemical composition and molecular structure of living
cells [22-24]. To date, only a few studies have been published integrating MRI and SERS
for multimodal bioimaging [17, 18], even though this combination can achieve both high
resolution and high sensitivity. We previously reported a gadolinium-doped mesoporous
silica nanoparticle (Gd2O3@MCM-41) as an efficient MRI contrast agent for cancer
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imaging [25, 26]. In addition, we incorporated the gadolinium-doped mesoporous silica
nanoparticle and gold nanoparticle (AuNP) into one single nano-system to form a
composite

Gd-Au

nanostructure

(Gd2O3@MCM-41@Au)

[27].

The

Gd-Au

nanocomposite was an efficient amplification strategy to increase MRI signals for in vivo
cancer imaging. MRI alone did not show enough sensitivity to study the relocation and
endocytosis of surface markers at subcellular level.
Epidermal growth factor receptor (EGFR) is a cell surface receptor tyrosine kinase
that, when activated by binding its specific ligands (e.g. EGF, TGF-α), triggers cell
signaling pathways that result in cell proliferation, inhibition of apoptosis, angiogenesis,
cell migration, adhesion and invasion [28, 29]. EGFR over-expression and up-regulation
have been reported in variety of cancers, including breast [30], lung [31], and esophageal
[32]. As a result, EGFR is the target in an expanding class of anticancer therapies [31, 33].
Here we report

synthesis and characterization of a Gd-Au nanocomposite

(Gd2O3@MCM-41@Au) functionalization to make it capable of SERS detection,
conjugation with a monoclonal antibody (mAb) to target EGFR and validation of function
human nasopharyngeal carcinoma (S18), epidermoid carcinoma (A431), and lung
adenocarcinoma (A549) cells. Importantly, SERS allowed mapping of EGFR cellular
distribution of EGFR on individual cancer cells in real time.
5.3 EXPERIMENTAL METHODS
5.3.1 Materials
4-mercaptobenzoic acid (MBA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC), N-hydroxysuccinimide (NHS), Tris-HCl, ß-glycerol phosphate,
EDTA, glycerol, triton X-100, sodium orthovanadate, benzamidine, aprotinin, leupeptin,
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phenylmethylsulfonyl fluoride, tween 20, phosphate buffer saline (PBS) and bovine serum
albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO). All solutions were
prepared using deionized water (18 MΩ cm-1). Monoclonal anti-EGFR antibody was
purchased from Life Technology (Carlsbad, CA). The polyethylene glycol (PEG) products,
Thiol-PEG-COOH and mPEG-Thiol, were purchased from Nanocs Inc. (New York, NY).
5.3.2 Preparation of the Gd-Au nanoprobe
The Gd-Au nanocomposite composed of Gd2O3-MCM41 silica nanoparticle and
gold (Au) nanoparticle were synthesized as previously described [26, 27]. The synthesized
Gd-Au nanocomposite was imaged by high-angle annular dark-field scanning electron
microscopy (HAADF-STEM, University of Oregon). The size distribution of the Gd-Au
nanocomposite was measured by dynamic light scattering (DynaPro NanoStar, Wyatt
Technology, Santa Barbara, CA).
The Gd-Au nanocomposite was sequentially coated with Raman reporter molecule
4-mercaptobenzoic acid (MBA), polyethylene glycol (PEG), and anti-EGFR antibody
(Life Technology, AHR5062) to achieve SERS capability, biocompatibility and specific
targeting as detailed below. Gd-Au (8.1 mg) was dissolved in phosphate-buffered saline
(10 mL) followed by addition of MBA solution (100 µL in 0.03 M in EtOH) before stirring
for 30 min. Then Thiol-PEG-COOH (1 mL, 0.24 mM, MW 5000) was introduced to react
for 30 min before 2.8 mL of mPEG-Thiol (0.42 mM, MW 5000) was added to stir for
another 3 hr. The resulting mixture solution was centrifuged (9700 g, 10 min) twice to
remove excess PEG molecules. The conjugation of monoclonal antibody was achieved by
using EDC/NHS method [34, 35] to activate the Gd-Au nanoparticle. PEGylated Gd-Au
nanocomposite was re-suspended in water. EDC (10 µL, 10 mM) and 10 µL of NHS
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solution (25 mM) were added to 1 mL of Gd-Au suspension (0.8 mg/mL) and incubated
for 30 min at room temperature. Activated Gd-Au suspension was then incubated with 20
µL of mAb EGFR (0.21 mg/mL) for 1 hr at room temperature. Excess antibody was
removed by centrifugation (9700 g, 10 min). The antibody functionalized Gd-Au bioprobes
were stored at 4 °C before measurements. The nanoparticles were stable for several days.
5.3.3 Cell culture, viability and sample preparation
All cells were purchased from ATCC and were determined to be free of
Mycoplasma contamination. Cells were grown at 37°C with 5% CO2 in a humidified
atmosphere. The human epidermoid carcinoma cell line A431 was cultured in Dulbecco’smodified eagle’s medium (DMEM) and Ham’s F-12 medium (1:1) with 10% fetal bovine
serum (FBS). The human lung carcinoma cell line A549 was cultured in F-12k medium
with 5% FBS and 1% penicillin-streptomycin. The human nasopharyngeal carcinoma cell
line S18 was cultured in DMEM with 10% FBS.
Cells were passaged at 80-90% confluence and seeded at a density of 105 cells per
2 mL of media. Cells were let grow for 24 hr after seeding before imaging measurements.
For Raman measurements, cells were seeded on magnesium fluoride (MgF2) substrates to
minimize the background noise. Cells were seeded on glass bottom Petri dishes for other
optical imaging measurements.
The cell viability was analyzed using LIVE/DEAD Viability/Cytotoxicity Assay
Kit (Invitrogen) according to manufacturer’s instructions.
5.3.4 Cellular SERS measurements
Raman measurements were performed by a Renishaw inVia Raman system
(Renishaw, UK) coupled with a Leica DMLM microscope (Leica microsystems, USA)
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equipped with a 785 nm near-IR laser. A 63X water immersion objective (NA = 0/90) was
used to image the cells in culture media and a temperature control unit (ALA Scientific
Instruments, USA) was used to keep cells under physiological temperature (37.5 °C). The
Raman instrument was calibrated with silicon at 520.5 cm-1.
Prior to Raman measurements, all three cell lines (A431, A549 and S18) were
incubated with anti-EGFR-conjugated Gd-Au nanoprobes for 1 hr and rinsed with PBS to
remove unbounded nanoparticles. Raman spectra (600~1800 cm-1) and Raman streamline
mapping (at 1075 cm-1) of the nanoprobe-treated cells were recorded under a laser intensity
of 3 mW. Spectra smoothing, baseline subtraction and mapping generation were performed
by Renishaw WiRE 3.3 software. Processed data were exported to Origin Pro 9 software
(OriginLab Corp., USA) for statistical analysis.
5.3.5 Cellular optical imaging
Fluorescence images of the nanoprobe-treated cells were collected by an Olympus
IX71 inverted fluorescence microscope equipped with an Olympus DP30BW CCD
camera. Dark field images were obtained by using an oil-immersed dark field condenser
(NA=1.5). Images were acquired with 40x objectives using DPController software
(Olympus).
5.3.6 Western blot
Cells were rinsed twice with ice-cold PBS and lysed in a buffer containing 25 mM
Tris-HCl (pH 7.4), ß-glycerol phosphate (50 mM), EDTA (0.5 mM), glycerol (5%), triton
X-100 (0.1%), sodium orthovanadate (1 mM), benzamidine (1 mM), and a protease
inhibitor cocktail containing aprotinin, leupeptin, and phenylmethylsulfonyl fluoride.
Protein concentration was determined using a BCA assay (Pierce, Rockford, IL). Protein
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was denatured with Laemmli’s buffer at 95°C for 5 min and lysate (50 μg) was loaded to
each well. Proteins were separated using 10% SDS-PAGE gel electrophoresis and resolved
proteins were transferred to PVDF before incubating in Tris-buffered saline containing
Tween-20 (0.05%) and fat-free dry milk (5%) for 1 hr at room temperature. Membranes
were incubated with primary antibodies to EGFR and β-Actin overnight at 4°C and
subsequently with HRP-conjugated secondary antibody at room temperature for 1 hr.
Signals were visualized using ECL (Pierce, Rockford, IL) following manufacturer’s
instructions.
5.3.7 Immunofluorescence imaging
S18, A431 and A549 cells grown on coverslips for 24 hr were fixed using 4%
paraformaldehyde for 20 min and permeabilized using 0.1% trion X-100 for 10 min. After
blocking with 5% BSA in PBS, cells were incubated with anti-EGFR antibody conjugated
with Alexia Fluor 555 at 1:50 dilution in 5% BSA solution overnight at 4°C. After washing
the cells thrice with PBS, the cover slips were mounted using Vectashield mounting
solution containing the nuclear counter-stain 4’, 6-diamidino-2-phenylindole (DAPI).
Images were collected under a Nikon inverted epifluorescence microscope. Representative
images were combined and processed using ImageJ software.
5.4 RESULTS AND DISCUSSION
5.4.1 Characterization of the Gd-Au nanocomposite
The synthesized Gd-Au nanoparticle has a composite structure illustrated in Figure
5.1a. Gadolinium oxide (Gd2O3) nanoparticles were embedded in the mesoporous silica
structure (MCM-41). Gd2O3-MCM41 is conjugated with gold (Au) nanoparticles through
a polymer linker polyethylenimine (PEI). The structure of the Gd-Au nanocomposite can
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be visualized by HAADF-STEM imaging (Figure 5.1b). Energy dispersive X-ray (EDX)
spectrum (supporting information, Figure 5.2a) and the elemental mapping (Figure 5.1c)
have presented the existence of gadolinium and gold, indicating the successful assembly
of the core-shell like structure of the Gd-Au nanocomposite. A line profile of integrated
intensity plot shows the elemental distribution across the nanocompostie (Figure 5.2b). The
hydraulic diameter is measured to be 208.05 ± 5.98 nm using dynamic light scattering
(DLS) (Figure 5.1d).
5.4.2 Functionalization of the Gd-Au nanocomposite
To make the Gd-Au nanocomposite a specific SERS probe for EGFR sensing and
imaging, step-by-step fucntionalization was conducted. As presented in Figure 5.3a, GdAu nanoparticles were firstly conjugated with 4-mercaptobenzoic acid (MBA) through AuS covalent bond as a Raman reporter molecule. The reasons to use MBA were: (1) MBA
can produce high SERS effect when binding with gold nanoparticle due to its high binding
affinity with gold and relatively large cross section area for Raman scattering [36]; (2)
MBA has simple SERS spectrum in the fingerprint region (600~1800 cm-1) with two
intensive characteristic peaks at 1075 and 1587 cm-1. The presence of both characteristic
peaks on spectra of nanoparticle-treated S18 cells (Figure 5.3b) confirmed the successful
adsorption of MBA on the Gd-Au nanocomposite. Then, thiolated PEG linkers were also
coated onto Au surfaces (PEG-NP) to eliminate the non-specific particle-cell binding as
well as to improve the biocompatibility of the Gd-Au nanoprobes when incubated with
cells in vitro. Lastly, to realize specific EGFR targeting, monoclonal antibody to EGFR
was introduced and conjugated with the PEGylated Gd-Au nanocomposite using
EDC/NHS method. The antibody-targeted Gd-Au nanoprobe (mAb-NP) was then used for
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in vitro SERS detection of EGFR and SERS imaging of cellular EGFR distribution at single
cell level.
5.4.3 Specificity of EGFR targeting
In order to study how anti-EGFR functionalized Gd-Au nanoprobes specifically
bind to EGFR and are subsequently internalized via receptor-mediated endocytosis, control
experiments are performed under different conditions. S18 cells (EGFR-positive)were
incubated with Gd-Au nanoprobes under three conditions: (1) PEG-NP for 1 hr; (2) mAbNP for 1 hr; and, (3) pre-blocked with free anti-EGFR antibody for 1 hr, followed by
incubation with mAb-NP for 1 hr. Cells were rinsed with PBS thrice to remove unbound
nanoprobes, before Raman measurements.
Typical Raman spectra are shown in Figure 5.3b. Cells with PEG-NP incubation
typically present a much lower SERS signal compared to cells incubated with mAb-NP,
while cells in the pre-block group (block-mAb-NP) show almost non-observable SERS
spectra (Figure 5.3c). Moreover, as shown in Figure 5.3c, the average intensities at 1075
cm-1 calculated from 50 spectra (1 cell/spectra) for each condition confirm the same finding.
S18 cells alone (CTRL) or treated with PEG-NP or mAb-NP were also visualized using
dark field imaging (Figure 5.3d). PEG-NP–treated cells exhibit minimal light scattering,
similar to CTRL, while cells incubated with mAb-NP have many more bright spots,
indicative of nanoparticles binding to the cells.
Thus, both SERS and dark field imaging indicate that the Gd-Au nanoprobes bind
to the S18 cells through a selective antibody-antigen recognition. Nonspecific binding was
minimal (i.e., few PEG-NP particles and low SERS signal) and selective (i.e., significant
suppression when pre-blocked with free anti-EGFR). High SERS signal was only observed
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in cells incubated with mAb-NP, indicating that the Gd-Au nanoprobe is capable of specific
SERS detection of EGFR.
5.4.4 Biocompatibility of the Gd-Au nanoprobe
To investigate the biocompatibility of the Gd-Au nanoprobe, viability of S18 cells
was measured following incubation with mAb-NPs at different concentrations (8, 20, 28,
40 and 48 µg/ml) for 24 hr. As shown in Figure 5.4, the cell viability remains >90% even
at the highest concentrations. For further SERS detection studies, a dose of 40 µg/ml was
chosen.
5.4.5 SERS mapping of cellular EGFR distribution
Raman mapping is generated by firstly taking spectral acquisition (2s exposure)
centered at 1100 cm-1 (400 cm-1 bandwidth) at each point over the 2D area of a single cell
with 0.8 μm spacing. Then, color mapping with the peak intensity at 1075 cm-1 is plotted
to depict the intensity variation over the area, which reflects the cellular EGFR distribution
via the binding of Gd-Au nanoprobes.
Changes of cellular EGFR distribution were measured (Figure 5.5). A single S18
cell after 1 hr incubation with mAb-NPs is presented in the Raman bright field image
(Figure 5.5a). In situ Raman mapping is performed over the area of cell body (dotted area
in Figure 5.5a) at 60, 90 and 120 min. As shown in Figure 5.5b-d, the bright spots, which
represent EGFR molecules, are heterogeneously distributed and are relocating in the cell.
Figure 5.5e-g show the Raman spectra at the same position (green crosses) in the mappings
at different times (Figure 5.5b-d). The time-dependent changes indicates the reorganization
of cell membrane after nanoparticle binding. The membrane reorganization is most likely
due to internalization of nanoprobes after binding through a receptor-mediated endocytosis,
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as suggested by a decreased mapping intensity with longer incubation (Figure 5.6). The
results of in situ Raman mapping have demonstrated the feasibility of the methodology to
detect and monitor dynamic cellular processes, although the mechanisms underlying the
cellular relocalization will require additional studies.
5.4.6 EGFR detection in three human cancer cell lines (S18, A431 and A549)
The proof-of-concept studies with S18 were validated using two unrelated human
cancer cell lines. As shown in Figure 5.7, SERS mapping shows EGFR in discrete domains
on each cell, but at different intensities, suggesting that the EGFR expression varies
between the cell lines.
To verify the EGFR levels, average Raman peak intensity at 1075 cm-1 was
calculated using data from 50 cells (1 spectrum/cell) in each cell line. A431 cell had
significantly (**P<0.01, one-way ANOVA) higher EGFR level than S18 or A549 cells
(Figure 5.8a). These observations were consistent with the western blot (i.e., EGFR band
is darker in A431 than S18 and A549, Figure 5.8b) and immunofluorescence imaging
(Figure 5.9). Importantly, SERS has the advantage over immunofluorescence because there
is no photo-bleaching. Since SERS has narrower spectral bands than fluorescence, it
represents a better candidate for multiplex imaging in complex biosystems.
5.5 CONCLUSION
In conclusion, we have synthesized a gadolinium-gold composite nanoparticle and
functionalized this nanoparticle for specific in vitro detection and imaging of EGFR using
surface-enhanced Raman scattering. Applying this Gd-Au nanoprobe, EGFR expression
level and cellular distribution were detected by SERS, and confirmed with immunoblotting
and immunofluorescence imaging. SERS shows the advantage of non-invasive detection
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over immunoblotting and immunofluorescence. In addition, changes in single cell EGFR
distribution could be monitored in situ, demonstrating the potential of SERS to study cell
activity under physiological conditions. These SERS results, combined with previously
reported MRI results [27], demonstrate the potential of this Gd-Au composite nanoparticle
as a multifunctional nanoprobe not only for the early detection and localization of cancer
in vivo, but also for the investigation of cancer metabolism and biochemistry at single cell
level.
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Figure 5.1 (a) Schematic illustration of the Gd-Au nanocomposite. (b) HAADF-STEM
image of the Gd-Au nanocomposite. (c) EDX elemental mapping of oxygen (O), silicon
(Si), gadolinium (Gd) and gold (Au) within the area labeled with an orange square in (b).
(d) Hydraulic diameter of the nanocomposite determined by DLS.
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Figure 5.2 (a) Parallel beam EDX spectrum of Gd-Au nanocomposite. (b) STEM image
and corresponding elemental line profile of the Gd-Au nanocomposite.
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Figure 5.3 (a) Schematic of the functionalization of Gd-Au nanocomposite. (b) Typical
Raman spectra (600~1800 cm-1) and (c) average Raman intensity at 1075 cm-1 of S18 cells
under the treatments of PEG-NP, mAb-NP, and first free anti-EGFR molecules then mAbNP. Error bar represents standard error of mean (SEM). (d) Dark field images of S18 cells
alone (CTRL), cells incubated with PEG-NP, and cells incubated with mAb-NP.
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Figure 5.4 Live/dead fluorescent images of S18 cells with mAb-NP incubation at
concentrations of 8, 20, 28, 40 and 48 µg/ml. Cell viability is analyzed in the column
graph.
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Figure 5.5 (a) Bright field image of a single S18 cell with 1-h incubation with mAb-NP
and the selected area for Raman mapping. Scale bar: 10 μm. (b-d) Raman images of the
selected area after 60, 90 and 120 min incubation, respectively. The color scale is generated
using peak intensity at 1075 cm-1. (e-g) Extracted Raman spectra at the same position
(green crosses) in (b-d).
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Figure 5.6 Single cell Raman mapping of S18 cells after 120, 135, 150, 165, 180 and 195
min incubation of Gd-Au nanoprobes. The color scale is generated with peak intensity at
1075 cm-1 and is kept constant with Figure 5.5.
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Figure 5.7 Representative Raman images of single S18, A431 and A549 cells incubated
with Gd-Au nanoprobes (mAb-NPs). The first row shows bright field image and the
selected area, and second row shows the corresponding Raman images. The color scale is
generated with peak intensity at 1075 cm-1 and is kept constant with Figure 5.5.
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Figure 5.8 (a) Average peak intensity at 1075 cm-1 for S18, A431 and A549 cells with GdAu nanoprobes incubation. Data are collected from 50 spectra for each sample. **P<0.01.
(b) Western blot result showing EGFR expression levels in S18, A431 and A549 cells.
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Figure 5.9 Immunofluorescence images showing the EGFR expression in S18, A431 and
A549 cells.
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CHAPTER 6
SERS-FLUORESCENCE BIMODAL IMAGING OF FATTY ACID RESPONSIVE
RECEPTOR GPR120
6.1 ABSTRACT
G-protein-coupled receptor 120 (GPR120), as a member of the rhodopsin family of
G-protein-coupled receptors, has been shown to function as a sensor for dietary fat in the
gustatory and digestive systems. Its specific role in the chemoreception of fatty acids,
which is thought to be crucial in understanding mechanism of fat intake and treatment of
obesity, remains unclear. Here we report a novel imaging technique using surfaceenhanced Raman spectroscopy (SERS)-fluorescence bimodal nanoprobes for detection and
imaging of GPR120 in single living cells. Construction and characterization of the bimodal
nanoprobes are described in detail. Biocompatibility and imaging capability of the probes
are investigated using a model HEK293 cell line with a inducible GPR120 gene
transfection. Cellular distribution of GPR120 are visualized by single-cell SERS and
fluorescence imaging. A dose-dependent GPR120 response to linoleic acid (LA) treatment
is measured by SERS.
6.2 INTRODUCTION
Dietary lipids (e.g. fatty acids, triglycerides) make up as high as 40% of daily
caloric intakes in Western diet, which is thought contribute greatly to the prevalence of
obesity and associated diseases [1-3]. Understanding the mechanisms underlying the
perception of dietary lipids thus is important to help control fat intake preference and
develop treatment of obesity. G protein-coupled receptors (GPCRs) have been shown to
play important roles in cellular signaling pathways that affect human sense of taste (e.g.
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sweet, bitter) [4, 5]. GPR120 and GPR40, members of GPCR family, have recently been
reported to mediate response to long chain fatty acids (LCFAs) [6]. Both GPR120 and
GPR40 knock-out mice showed a diminished preference for linoleic acid and oleic acid,
and diminished taste nerve responses. In addition, studies have shown that GPR120 and
CD36, LCFA receptors identified in rodent taste bud cells, mediate differential Ca2+
response to fatty acids, and are differentially regulated by dietary lipids [7, 8]. Though
several lipid receptor candidates (e.g. GPR120, GPR40, and CD36) have been found in the
tongue papillae, the mechanism how these receptors act in the perception of LCFAs
remains unresolved and merits further extensive studies [3]. It will be beneficial to develop
an imaging technique that can visualize how these receptors act when binding with LCFAs
in single cells, in order to understand their specific roles in fat perception.
Surface-enhanced Raman spectroscopy (SERS) is a novel and powerful optical
imaging technique that can be applied in single cell bioanalysis. SERS is able to achieve
10~14 orders of magnitude enhancement of spontaneous Raman signal by conjugate a
molecule to a noble metal (e.g. Au, Ag) nanostructure [9], which allows detection of
biomolecules with ultrahigh sensitivity [10, 11]. To generate SERS activity, a SERS
nanoprobe composed of noble metal nanoparticle, Raman reporter molecule, and surface
stabilizer are usually constructed and applied. Due to advantages of high stability and
biocompatibility, especially great capability of multiplex detection, SERS nanoprobes have
been applied in a variety of bioapplications such as molecular detection [12, 13], single
living cell imaging [14-16], and in vivo biosensor [17, 18]. In addition, SERS imaging, by
generating a pseudo-color map based on relative intensities of selected Raman bands, is
able to map the distribution of biomolecules such as lipids and proteins [19, 20], cell
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surface receptors [17, 21] and even bacterial species [22, 23] at single cell level. However,
SERS is a low-throughput imaging technique and it requires a long acquisition time (e.g.
several seconds) to get reliable Raman spectrum, due to relatively weak signal by Raman
scattering (even after SERS enhancement). This limits the application of SERS in
biological analysis, especially for high-throughput cell sorting and imaging [24].
To overcome the limitation and expand the functionality, multimodal imaging
probes have been developed to integrate SERS with other imaging modalities, such as
magnetic resonance imaging (MRI) [25], X-ray computed tomography (CT) [26, 27] and
fluorescence imaging [28-30]. Among these modalities, fluorescence, due to its fast
imaging speed and high-throughput imaging ability, is considered as a promising
complementary technique to SERS. Fluorescence functions for quick recognition of the
analytes in complex biosystems, while SERS is used to accurately detect multiplex targets
in single cells. Recently, Choo et al. [31] reported a SERS-fluorescence bimodal imaging
technique to investigate multiple cancer markers co-localized in single breast cancer cells.
Here we developed a SERS-fluorescence bimodal nanoprobe for detection and
imaging of GPR120 in single cells. Europium-doped calcium molybdate nanoparticles
(CaMoO4:Eu3+) showed intense red fluorescence emission under UV light excitation [32].
This fluorescence-active CaMoO4:Eu3+ nanoparticle was conjugated with SERS-active
gold nanorods (AuNR) encapsulated with Raman reporter molecule 4-mercaptobenzoic
acid (MBA), to realize SERS-fluorescence dual functions. The composite nanoparticle was
conjugated with antibody for specific targeting of GPR120 expressed in living cells. By
using this bimodal nanoprobe, we successfully realize SERS-fluorescence imaging
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specifically for GPR120 at single cell level. In addition, for the first time, we observed a
linear dose-dependence of GPR120 on linoleic acid (LA) treatments.
6.3 MATERIALS AND METHODS
6.3.1 Materials
4-mercaptobenzoic

acid

(MBA),

N-(3-Dimethylaminopropyl)-N’-

ethylcarbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), doxycycline
hydrochloride (DOX), linoleic acid (LA), europium(III) nitrate hydrate (Eu(NO3)3·xH2O)
were purchased from Sigma-Aldrich (St. Louis, MO). Calcium nitrate tetrahydrate,
(Ca(NO3)2·4H2O), ammonium molybdate (H8MoN2O4), oleic acid, 1-octadecene were
purchased from Alfa Aesar (Ward Hill, MA). Blasticidin S HCl, Hygromycin B,
phosphate-buffered

saline

Viability/Cytotoxicity

Assay

(PBS),
Kit

0.5%
were

trypsin-EDTA,

purchased

from

Life

LIVE/DEAD
Technologies

(Carlsbad, CA). The polyethylene glycol (PEG) products, thiol PEG acid (HS-PEG-COOH,
MW 5000) and methoxyl PEG thiol (mPEG-SH, MW 5000), were purchased from Nanocs
Inc. (USA). Polyclonal GPR120 antibody was purchased from Santa Cruz Biotechnology
Inc. (sc-99105). Ultrapure water (18 MΩ cm-1) was used in this work.
6.3.2 Characterization techniques
Transmission electron microscopy (TEM) images and energy-dispersive X-ray
spectroscopy spectrum (EDX) were acquired using an FEI Titan 80–300 kV (S) TEM
equipped with a spherical aberration (Cs) image corrector (300 kV). For the TEM
measurements, the powder samples were ground and dispersed in methanol. Few drop of
dispersed particles were placed on a carbon coated-copper grid and allowed to dry at room
temperature. Absorption spectra were acquired by Multiskan Spectrum spectrophotometer
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(Thermo Scientific). FT-IR spectra were acquired by Varian 660-IR FT-IR spectrometer
(Agilent Technologies). Luminescent spectra were acquired by FluoroMax-3 fluorometer
(Horiba Scientific). Raman spectra were measured by Renishaw inVia Raman
spectrometer equipped with a 785 nm near-IR laser, which was focused through a 63x
water immersion lens (NA=0.90, Leica Microsystems). Spectral smoothing and
autofluorescence background subtraction were performed using an automated algorithm
program kindly provided by BC Cancer Research Center [33]. The processed spectra were
exported to OriginPro 9 software for plotting. Data were reported as mean ± SE (standard
error of mean). Statistical difference was analyzed by one-way analysis of variance
(ANOVA).
6.3.3 Synthesis of CaMoO4:Eu3+@AuNR hybrid nanoparticles
Europium-doped calcium molybdate (CaMoO4:Eu3+) nanoparticles were prepared
via a simple thermolysis process ~309 oC. The preparation procedure can be briefly
described as follows: 21 mg of Eu(NO3)3 · xH2O, 50 mg of NaOH, and 1.0 g of
Ca(NO3)2.4H2O were dissolved in 2 mL of distilled water. The mixture was treated with 2
mL of OA and 18 mL ODE and heated in a round-bottom flask at 80 °C for 1 hr under
continuous stirring. In another beaker, 0.423 g of H8MoN2O4 was dissolved in 3 mL of DI
water, and 0.1 g of NaOH, 2 mL of OA, and 18 mL of ODE were added and stirred the
solution at 80 C for 1 hr. The two solutions were mixed under continuous stirring and
heated at 80 C for 30 min, and then the reaction was refluxed at 309 °C for 1 hr. The
resulting precipitate was collected by centrifugation at ~2500 g after washing with ethanol.
The obtained precipitate was cooled at room temperature for 2 days.
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For the synthesis of CaMoO4:Eu3+@AuNR hybrid nanoparticles, commercially
available Au nanorods (AuNRs) with 10 nm in diameter and 35 nm in length were
purchased from Nanopartz. Initially, 4 mL of the AuNR was centrifuged at 12000 g for 30
min to remove the excess of CTAB and then redispersed in PBS. Centrifugation was
repeated for three times to reduce the excess of CTAB present on the surface of the AuNR.
4 mL of AuNR dispersed in PBS was added to 1 mL of the PEGylated CaMoO 4:Eu3+
nanoparticles under continuous stirring and then sonicated for 1 hr. The resulting solution
was centrifuged, and the hybrid nanoparticles precipitated was collected. These particles
were washed with a PBS solution for three times and redispersed in PBS.
6.3.4 Functionalization of SERS-fluorescence bimodal probe
One mL of as-prepared CaMoO4:Eu3+@AuNR composite nanoparticle solution
was mixed with MBA solution (1mM, 10 µL) and reacted for 30 min. Solutions of HSPEG-COOH (1 mg/mL, 10 µL) and mPEG-SH (1 mg/mL, 40 µL) were sequentially added
to the nanoparticle solution and incubated for 2 hr. The resultant solution was then
centrifuged (12000 g, 15 min) to remove excess PEG and MBA. Particles were resuspend
in water. Freshly prepared EDC (10 mM, 10 µL) and NHS (25 mM, 10 µL) solutions were
mixed with the nanoparticle solution and reacted for 30 min. The resultant solution was
centrifuged and particles were resuspended in PBS. Finally, anti-GPR120 antibody (0.2
mg/mL, 10 µL) was added to the nanoparticle solution and reacted for 1 hr. Excess antibody
was removed by centrifugation. Nanoparticles were resuspended in PBS. The
functionalized nanoprobe (CaMoO4:Eu3+@AuNR-MBA-Ab) was stable in solution for
several days at 4 ºC.
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6.3.5 Cell culture
HEK293 cell lines transfected with an inducible GPR120 gene (HEK293-GPR120)
and a constitutive CD36 gene (HEK293-CD36) were used in this context. Cells were grown
in DMEM-GlutaMAX media (Life Technologies, 10569-010) supplemented with 10%
Tet-free fetal bovine serum (Fisher, NC0290780). Cells were cultured in a humidified
atmosphere at 37 ºC with 5% CO2, and were passaged at 80~90% confluence. Blasticidin
S HCl (10 µg/mL) and Hygromycin B (100 µg/mL) were added to cell culture medium
specifically for maintenance of inducible GPR120 gene. To express GPR120, HEK293GPR120 cells were induced with DOX at 0.5 µg/mL for 48 hr.
6.3.6 Cell staining and Viability test
The cell viability was analyzed using LIVE/DEAD Viability/Cytotoxicity Assay
Kit (Invitrogen) according to the manufacturer’s instruction. Briefly, (1) cells were cultured
in poly-D-lysine coated glass-bottom dishes (MatTek Cop. USA) for 24 hr; (2) cells were
then washed with PBS twice; (3) 2 ml of mixed solution of 2 µM Calcein AM and 4 µM
ethidium homodimer-1 (EthD-1) (both from Invitrogen) was added directly to cells, and
incubated cells for 30 min at room temperature; (5) cells were imaged using fluorescence
microscope to analyze the relative proportion of live/dead cells. A 10× objective was used
to observe fluorescence.
Calcein AM was well retained within live cells producing green fluorescence;
however, EthD-1 entered cells with damaged membrane and bonded to nucleic acids,
producing a red fluorescence in dead or membrane-damaged cells. Therefore, the live/dead
cells were differentiated visually.
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6.3.7 Cellular fluorescence and SERS imaging
For fluorescence and SERS imaging experiments, cells were incubated with the
functionalized nanoprobe (CaMoO4:Eu3+@AuNR-MBA-Ab) for 24 hr, and rinsed with
PBS 3 times before imaging experiments. For LA treatments, cells were first treated with
LA for 5 min at different concentrations, and then incubated with nanoprobes for 24 hr.
Cellular fluorescence imaging was performed on an Olympus IX71 inverted
microscope with an external 285 nm UV lamp. Images were acquired and processed using
DPController software (Olympus Corporation) to maintain identical light exposure for
three different cell conditions.
For SERS measurements, cells were seeded on a cleaned magnesium fluoride
(MgF2) optical window (United Crystals Co.) to minimize background signal from
substrate. Raman spectra between 600~1800 cm-1 were recorded under 10s laser exposure
(3mW). For each sample, 25 spectra from 25 cells with 1spectrum per cell were collected.
Raman mappings were generated using Renishaw WiRE 3.3 software.
6.4 RESULTS AND DISCUSSION
6.4.1 Nanoparticle Structure characterization
The typical TEM image of the composite CaMoO4:Eu3+@AuNR NPs is shown in
Figure 6.1a. It confirms the formation of hybrid nanoparticles where AuNR is attached to
the surface of CaMoO4:Eu3+ NP. The presence of each element in the particle was
confirmed by EDX spectrum (Figure 6.1a, inset). The average size of CaMoO4:Eu3+
nanoparticles is found to be ~20 nm, whereas, average lengths and widths of AuNR is
found to be ~40 and 10 nm, respectively. Moreover, the hybrid nanoparticles show high
dispersion for long-time without precipitation. The crystalline nature of the CaMoO4:Eu3+
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nanoparticles was confirmed by X-ray diffraction pattern (not shown here). All peaks are
well match with the tetragonal structure of CaMoO4:Eu3+ (JCPDF#29-0351). The UV-Vis
spectra of hybrid nanoparticles in the range 200–1000 nm are shown in Figure 6.1b. A
strong absorption bands at 512.5 and 789 nm was observed, which are assigned to
transverse and longitudinal surface plasmon resonance (SPR) bands of AuNR, respectively.
It is observed that the peak positions of SPR band at 789 nm is slightly red-shifted (~0.8
nm) and full width at half maximum (FWHM) increases by ~27 nm, whereas there is no
shift for SPR band at 512.5 nm and FWHM increased by ~14.4 nm on antibody coating
on the surface of nanoparticles. Moreover, a small hump ~265 nm was observed for
CaMoO4:Eu@AuNR NPs, this is ascribed to a charge transfer from the oxygen ligands to
the central molybdenum atom within the MoO42- cluster (also called Mo–O charge transfer
band (CTB)), but no such peak was observed for bare AuNR. It was further confirmed by
excitation spectra (λem = 615 nm). Also some weak peaks in the longer wavelength region
300–500 nm are ascribed to the direct 4f6–4f6 intraconfiguration transitions of Eu3+ ion
(Figure 6.1d, inset) [34]. The CaMoO4:Eu3+@AuNR NPs emits strong red fluorescence
under 270, 285, 300, 395, and 464 nm excitations (Figure 6.1d) peaks centered at 590
(5D0→7F1; magnetic dipole transition) and 615 nm (5D0→7F2; electric dipole transition).
The high-energy state excited (Mo–O CTB and Eu3+) electrons of Eu3+ are unstable and
relaxed back to back to ground states of Eu3+ ion through photons emission in visible region.
The intensity of 5D0→7F2 transition is significantly higher than other transitions of Eu3+
ion [35]. Strong luminescence of CaMoO4:Eu3+@AuNR NPs may be particularly useful
for biological fluorescence labeling.
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Figure 6.1c shows the FT-IR spectra of bare CaMoO4:Eu3+, CaMoO4:Eu3+@AuNR,
and antibody-conjugated CaMoO4:Eu3+@AuNR hybrid nanoparticles in the range from
4000–500 cm-1. Peak at ∼1650 and 3450 cm−1 correspond to bending and stretching
vibrations of H–O–H molecules present on the surface of the hybrid nanoparticles. The
characteristic peaks appears ~802 cm−1 is assigned to asymmetric stretching vibration of
O–Mo–O vibration in the MoO42− tetrahedron [36]. The peaks at 2923 and 2852 cm-1
indicating the C–H streaching vibrations arises from OA [37]. On antibody conjugation to
CaMoO4:Eu3+ nanoparticles with AuNR and AuNR-Ab the peaks become broaden. The
FTIR spectrum of pure HS–PEG–COOH, mPEG-HS, and antibody are show in Figure 6.2.
It was found that pure HS–PEG–COOH has sever characteristic peaks between 1700–1000
cm-1, whereas some feeble peaks were observed ~2500, 1244, and 1076 cm-1 for antibody.
Moreover, the conjugation of the antibody to the CaMoO4:Eu@AuNR nanoparticles results
some small peaks between 1700–1000 cm-1 which are characteristic of peaks arises from
PEG and/or antibody present on the surface of the nanoparticles. It further confirms the
presence of antibody coating on the surface of the particles.
6.4.2 Functionalization and performance of SERS-fluorescence bimodal probe
As prepared CaMoO4:Eu3+@AuNR nanocomposite was further functionalized to
generate intense Raman signals and achieve specific targeting. Figure 6.3a demonstrate the
functionalization process containing three steps: (1) MBA, as a Raman reporter molecule
providing strong chemical enhancement of the SERS signal and simple SERS spectrum,
was conjugated onto the nanocomposite through covalent Au-S bond. (2) PEG linkers were
coated to improve the stability and biocompatibility of the nanoprobe, as well as to
minimize the non-specific binding of the nanoprobes to cells. (3) Finally, anti-GPR120
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antibodies were conjugated onto the nanocomposite to realize specific GPR120 targeting
in cells. The specificity of GPR120 antibody was determined by immunofluorescence
imaging (Figure 6.4). Under 1:250 dilution ratio, the antibody exhibited good specificity
in labeling GPR120 in cells. Thus, this ratio was used in nanoprobe functionalization and
cell incubation.
The performance of functionalized nanoprobe (CaMoO4:Eu3+@AuNR-MBA-Ab)
was assessed by SERS and fluorescence imaging. The constructed probes were incubated
with cells for 24 hr at final concentration of 100 μg/mL. Three different cell samples are:
(1) HEK293-GPR120 cells induced with DOX for 48 hr (GPR120 (+)); (2) HEK293GPR120 cells without DOX inducing (GPR120 (-)); (3) constitutive HEK293-CD36
(CD36) cells. Representative SERS spectra of the nanoprobe-treated cells are shown in
Figure 6.3b. Typical spectrum of GPR120 (+) cells shows two enhanced peaks at 1078 and
1585 cm-1, which are assigned to the ring breathing and axial deformation modes of MBA,
respectively [38, 39]. In contrast, spectra of GPR120 (-) and CD36 cells show nearly no
Raman peaks from the reporter molecule MBA, but only regular Raman signals from cells
(e.g. 1003 cm-1 from phenylalanine). Average peak intensity at 1078 cm-1 for GPR120 (+)
cells is significantly higher (P<0.001, N=25) than GPR120 (-) and CD36 cells (Figure 6.3c).
This difference is resulted from the specific targeting ability of the constructed nanoprobe
CaMoO4:Eu3+@AuNR-MBA-Ab, which selectively binds to GPR120 (+) cells through
specific antibody-antigen interactions, bringing significantly enhanced SERS signal. This
finding can also be confirmed by fluorescent images, in which the CaMoO4:Eu3+@AuNRMBA-Ab nanoprobe-incubated GPR120 (+) cells exhibited considerable red fluorescence
while the fluorescence of GPR120 (-) cells was almost invisible (Figure 6.5).
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6.4.3 Biocompatibility
Biocompatibility

of

the

SERS-fluorescence

bimodal

nanoprobe

CaMoO4:Eu3+@AuNR-MBA-Ab was estimated by incubating GPR120 (+) cells with the
nanoprobes at different concentrations (20, 50, 80, 100, 200 μg/mL) for 24 hr, and then
testing the cell viability using live/dead fluorescence imaging. As shown in Figure 6.6,
there were no significant decreases in cell viability when incubating cells with nanoprobes
at concentration as high as 100 μg/mL. Thus, this concentration (100 μg/mL) was chosen
in further imaging experiments.
6.4.4 Cellular fluorescence and SERS imaging
Cellular imaging capability of the bimodal nanoprobe was estimated by
fluorescence and SERS imaging. Fluorescent images of nanoprobe-treated multiple cells
successfully demonstrated the difference in GPR120 levels between DOX-induced and
non-induced HEK293-GPR120 cells (Figure 6.5). Besides, due to its high-throughput
nature, fluorescence was also used to quickly identify individual cells with high GPR120
expression levels. At single cell level, as shown in Figure 6.7, CD36 cell showed hardly
visible red fluorescence at the central area of the cell (Figure 6.7b); on the other hand,
GPR120 (+) cell had strong red color all over the cell (Figure 6.7d). Because the
nanoprobes were conjugated with anti-GPR120 antibodies, they tended to bind with
GPR120 but not CD36 at cell surface.
Furthermore, cellular SERS imaging was performed on the nanoprobe-treated cells.
SERS images were created using the Raman intensities of peak 1078 cm-1, which is the
most stable and reproducible characteristic peak from the reporter molecule, MBA. By
collecting the peak intensity values all over the cell and transforming them into color values,
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GPR120 distribution were reflected by the brightness of the SERS image at single cell or
subcellular level. Figure 6.8 showed the single-cell SERS mapping of GPR120. Apparently,
strong SERS signals were recorded on GPR120 (+) cell (Figure 6.8d), while SERS signals
at the CD36 cell were nearly undetected (Figure 6.8b). SERS imaging is able to mapping
the heterogeneous distribution of GPR120 receptors at single cell level, providing more
accurate spatial information than regular fluorescence imaging.
6.4.5 Detection of GPR120 under LA treatment by SERS
GPR120 responses to LA treatments were measured by SERS. GPR120 (+) cells
were treated with LA at concentrations 0, 5, 20, 30, and 60 µM for 5 min, and then
incubated with nanoprobes for 24 hr. After washing off the unabsorbed nanoparticles, cells
were taken for Raman measurements. Figure 6.9a showed the average SERS spectra (N=25)
of the LA-treated cells. Two major intense peaks at 1078 and 1585 cm-1 were from the
nanoprobes, which represent the activity level of GPR120 receptors. Elevated SERS
signals were observed in high LA concentration treatments (Figure 6.9b, inset). Peak
intensity at 1078 cm-1 vs. LA concentration was plotted in Figure 6.9b. It was found that
there is a linear relationship (R2 = 0.93) between the SERS intensity and LA concentrations.
This result indicates GPR120 activity is up-regulated by LA treatment, which is consistent
with previous reports using other methods [7]. Furthermore, for the first time, we found
that there is a linear dose-dependence of GPR120 to LA in 0~60 µM concentration range.
6.5 CONCLUSIONS
In summary, we developed a dual functional composite nanoprobe for SERSfluorescence bimodal imaging of fat-responsive receptor GPR120 in single living cells.
The dual functional nanoprobe was composed of europium-doped calcium molybdate and
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gold nanorod, and further functionalized with Raman reporter and anti-GPR120 antibody.
The functionalized nanoprobe was successfully applied for both SERS and fluorescence
detection of GPR120 in different cell lines. Fluorescence served as an indicator for fast
recognition of the target, while SERS functions for accurate localization of molecular
signature in single cells. In particular, cellular distribution of GPR120 was successfully
detected by single-cell SERS mapping. Taking advantages of the quantification ability of
SERS, we observed an up-regulation of GPR120 by LA treatment. Moreover, a linear
relationship between GPR120 activity and LA concentration in 0~60 µM range was
observed for the first time. Our future direction is to build multiplex imaging probes for
simultaneous detection of major lipid receptors such as GPR120, GPR40 and CD36, trying
to unveil the enigma how these receptors interact with each other in the chemoreception of
fatty acids.
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Figure 6.1 Characterization of the nanoprobe. (a) TEM image of CaMoO4:Eu3+@AuNR
nanoparticle. Inset: EDX spectrum of the particle. (b) UV-Vis absorption spectra of AuNR
and

CaMoO4:Eu3+@AuNR.

(c)

FT-IR

spectra

of

bare

CaMoO4:Eu3+,

CaMoO4:Eu3+@AuNR, and antibody-conjugated CaMoO4:Eu3+@AuNR. (d) Luminescent
properties (excitation/emission) of the CaMoO4:Eu3+@AuNR nanoparticle.
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Figure 6.2 FT-IR spectra of (a) HS–PEG–COOH, mPEG-HS and (b) GPR120 antibody.
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Figure 6.3 (a) Schematic for functionalization process of CaMoO4:Eu3+@AuNR
nanocomposite. (b) Representative SERS spectra and (c) average SERS intensities at 1078
cm-1 (N=25) of CaMoO4:Eu3+@AuNR-MBA-Ab nanoprobe-incubated cell samples: (1)
HEK293-GPR120 cells induced with DOX (GPR120 (+)); (2) HEK293-GPR120 cells
without DOX inducing (GPR120 (-)); (3) constitutive HEK293-CD36 (CD36) cells.
**P<0.001.
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Figure 6.4 Immunofluorescence imaging to test the specificity of GPR120 antibody.
Antibody ratio: 1st 1:250, 2nd 1:500. Color: red—GPR120, blue—DAPI.
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Figure 6.5 Fluorescence imaging of GPR120 (+) and GPR120 (-) cells incubated with
CaMoO4:Eu3+@AuNR-MBA-Ab nanoprobe for 24 hr.
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Figure 6.6 Viability of GPR120 (+) cells with 24-hr incubation of CaMoO4:Eu3+@AuNRMBA-Ab nanoprobe at concentrations of 20, 50, 80, 100, and 200 μg/mL. Green
fluorescence presented live cells, whereas red fluorescence showed dead or membranedamaged cells. Over 300 cells were counted for each treatment condition. Scale bar: 200
μm. **P<0.001.
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(a)

(b)

(c)

(d)

Figure 6.7 Phase contrast (a, c) and Fluorescence (b, d) images of single CD36 (a, b) and
GPR120 (+) (c, d) cells incubated with CaMoO4:Eu3+@AuNR-MBA-Ab nanoprobes for
24 hr.
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(a)

(b)

(c)

(d)

Figure 6.8 Bright field images (a, c) and Raman mappings (b, d) of single CD36 (a, b) and
GPR120 (+) (c, d) cells incubated with CaMoO4:Eu3+@AuNR-MBA-Ab nanoprobes for
24 hr. Raman mappings were generated by the selection of peak 1078 cm-1. The intensities
were normalized between the lowest (0) and highest (1) color values. Scale bar: 5 μm.
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(a)

(b)

Figure 6.9 GPR120-LA dependence measured by SERS. (a) Average Raman spectra of
CaMoO4:Eu3+@AuNR-MBA-Ab nanoprobe-incubated cells under 5 min LA treatment at
concentrations 0, 5, 20, 30, and 60 μg/mL. (b) Linear relationship (R2=0.93) between SERS
intensity (1078 cm-1) and LA concentration. Inset: expanded Raman spectra around 1078
cm-1.
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CHAPTER 7
SUMMARY AND FUTURE DIRECTION
7.1 SUMMARY
The overall objective of this dissertation is to study human disease at single cell
level using advanced instrumentation including atomic force microscopy (AFM), Raman
spectroscopy and fluorescence microscopy. Research presented in five technical chapters
(chapter 2-6) can be summarized as following:


Apply atomic force microscopy (AFM) and Raman spectroscopy to measure
cellular biomechanical and biochemical properties for classification of cells in
different conditions.



Design and synthesize nanoparticle-based probes for highly sensitive and specific
imaging and detection of cell surface receptors using surface-enhanced Raman
scattering (SERS), AFM-based nanoscale recognition and fluorescence microscopy.
In chapter 2, we measured the biomechanical and biochemical properties of healthy

and cancerous (SAEC & A549) human lung epithelial cells, and compared their responses
to short-term (4 hr) anticancer drug doxorubicin (DOX) treatments, using AFM and Raman
spectroscopy. Some key research findings are: (1) cancerous A549 cell is less stiff and less
adhesive than healthy SAEC cell. (2) After DOX treatment, A549 gets stiffer and more
adhesive while SAEC respond oppositely, resulting a reduced difference in biomechanics
between two cell lines. (3) DOX treatment causes decrease in DNA but increase in protein
and lipid contents in both cell lines. We also discussed the potential correlation between
the biomechanics measured by AFM and the biochemical composition measured by Raman
spectroscopy, and suggested a series of experiments to study the correlation.
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In chapter 3, a gold nanorod (AuNR)-based SERS nanoprobe was developed for
single-cell analysis of epidermal growth factor receptor (EGFR). The SERS probe was able
to specifically target EGFR in single breast cancer cell and generate characteristic Raman
peak that can be used determine the localization of EGFR on cell membrane surface.
Quantification of EGFR expression level was performed using SERS and confirmed by
immunoblotting. In addition, cellular distribution of EGFR was visualized by single-cell
SERS mapping, which provides more detailed spatial resolution at single cell level
comparing with traditional immunofluorescence imaging. EGFR-mediated nanoparticle
endocytosis was also investigated by depth SERS mapping, demonstrating the potential of
SERS, as a noninvasive technique, to study dynamic cellular process.
Chapter 4 described an AFM-based recognition imaging technique—simultaneous
Topography and RECognition (TREC) imaging—for nanoscale imaging of EGFR.
Experiments on mica demonstrated high specificity, reproducibility and efficiency of
TREC imaging technique for EGFR recognition. Single molecule recognition of EGFR
was achieved in fixed and living breast cancer cells. TREC imaging exhibited potential to
monitor cellular activities like receptor-ligand binding at single molecule level.
Chapter 5 introduced a previously reported MRI contrast agent Gd-Au
nanocomposite. We further functionalized the composite Gd-Au nanoprobe to integrate
SERS function and tested its SERS performance. Our results showed that composite GdAu nanoprobe successfully served as a SERS probe for single-cell mapping of EGFR as
well as quantification of EGFR levels in different cancer cells, showing the potential of
this nanoprobe for MRI-SERS multifunctional detection and bioimaging.
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In chapter 6, we developed a SERS-fluorescence dual functional nanoprobe for in
vitro imaging of fat-responsive GPR120 receptor. We tested the performance of this
nanoprobe for specific imaging of GPR120 using SERS and fluorescence imaging.
Furthermore, by using SERS, we observed a dose-dependent GPR120 response to linoleic
acid treatment. Our results showed a bright perspective to study fat receptors and their
interaction with fatty acids using SERS.
7.2 FUTURE DIRECTION
7.2.1 Cellular analysis of human diseases by AFM and Raman spectroscopy
In this dissertation, I included a study that uses our tandem AFM/Raman system to
measure the biomechanical properties and biochemical composition of human lung cancer
cells (chapter 2), demonstrating the strength of our combined AFM/Raman system as an
noninvasive tool for cellular diagnosis of human diseases like cancer. In fact, due to the
noninvasive nature of this technique, and its ability to provide quantitative information for
cells, our AFM/Raman system can be applied for a range of different cell analysis. For
example, we have measured the changes in biomechanics and biochemical composition
during differentiation process of stem-like cells [1]. We also have investigated the toxicity
effects of diesel exhaust particles (DEPs) to human lung cells by measuring their
biomechanical and biochemical responses [2]. Another ongoing project is that we are trying
to use our AFM/Raman instrumentation to study human lung cells in response to
inflammatory stimuli. We would also investigate human cellular response to air pollutant
like PM2.5.
Although AFM and Raman spectroscopy are techniques with great potential in cell
analysis, they only physical and basic chemical properties, and need to combine with other
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techniques for comprehensive analysis. In other words, since AFM and Raman
spectroscopy are not standard approaches for many biological assays, they need to be
validated by other tested methods. For example, in addition to the biomechanical and
biochemical properties measured by AFM and Raman spectroscopy, we could use
multiplex ELISA to measure cytokine and chemokine production to verify the
inflammatory responses of cells induced by DEP treatments. We could use quantitative
PCR to measure gene expression long with the biophysical and biochemical changes during
cell differentiation.
In summary, our AFM/Raman system has great potential in mammalian cell
analysis. It could provide supplementary information to conventional biological techniques
for better investigation of complicated biological problems. Thus using AFM and Raman
spectroscopy for studies human diseases at cellular level is still an important future
direction in our lab.
7.2.2 nanoparticle-based imaging probes for noninvasive bioimaging
Molecular imaging of human disease cells by nanoparticle-based imaging probes is
the major focus of this dissertation. Metallic nanoparticles (e.g. Au or Ag) showed
remarkable light scattering efficiency due to their strong surface plasmon resonance.
Especially for Au nanoparticles, the high photostability, water solubility and low
cytotoxicity make them favorable for biological imaging. In this dissertation, several
studies have been done using Au nanoparticle-based contrast agent for in vitro bioimaging.
A lot more experiments could be performed in this direction in the future.
One project ongoing is to use Au nanoparticle-base imaging probe for multiplex
SERS detection of fat receptors GPR120 and CD36 at single cell level, because their roles
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in the chemoreception of fatty acids are thought to be critical for people to understand fat
preference and develop obesity treatments. In chapter 6 of this dissertation, we have
presented a study using SERS-fluorescence bimodal imaging technique to study GPR120
in single cells. However, we are more interested in the interactions between the two
receptors GP120 and CD36, even their interactions with fatty acids. From this perspective,
one experiment we can do is to build multiplex SERS probes, and use them to mapping
cellular distribution of both GPR120 and CD36 in same single cell. Moreover, we can
monitor their distribution change when fatty acid is introduced using single cell SERS
mapping. Even though SERS technique shows great promise for multiplex detection and
imaging, it still suffers the diffraction limit of optical imaging techniques. In order to
achieve nanoscale imaging resolution, we could apply tip-enhanced Raman scattering
(TERS), which uses an AFM probe instead of a laser to map the cell surface. Due to the
nanoscale imaging capability of AFM, TERS is promising to provide us the detailed spatial
information of GPR120 and CD36 distribution at subcellular level or even single molecule
level.
Another direction is multimodal in vivo boimaging. As discussed in previous
chapters, multimodal imaging can integrate advantages of different imaging modalities,
improving imaging performance in resolution and sensitivity. In this dissertation, I have
included two studies describing bimodal imaging probes for in vitro bioimaging (chapters
5 and 6). The sensitivity, specificity and biocompatibility of these probes have been tested
by in vitro experiments. It is very promising to apply these probes for more clinically
important in vivo imaging. One potential challenge is the long-term stability of these probes.
Will these probes maintain their stable structure in complex biological environments like

171
animal organs? What iss the retention time of these nanoprobes in animal body? There
questions need to be further investigated in future studies.
Besides the imaging application, there are many other biological application of
metallic nanoparticles that worth investigation in the future. For example, we could apply
Au nanoparticles for photothermal therapy (PTT) or photodynamic therapy (PDT) of
human cancers. My colleague Qifei Li from Dr. Anhong Zhou’s lab has done some initial
work on PTT and PDT of human cancer cells using Au nanoparticle-based nanoprobes. In
addition, we could also develop porous nanostructures as carriers for drug delivery and
controlled drug release. In a word, our future direction is to use advanced instrumentation
and nanotechnologies to help biologists solve more sophisticated biology problems.
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